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Prostate adenocarcinoma (PCa) is the second most frequently diagnosed cancer 
in males worldwide and the fifth leading cause of cancer death in men (Bray et 
al., 2018). In Estonia, according to 2017 data of the National Institute for Health 
Development, PCa was diagnosed in 1113 cases, making 25.2% of all diag-
nosed malignancies in men. It means that the analysis of histological samples in 
the form of biopsies, chips, or prostatectomy samples of the prostate makes a 
significant part of pathologistsʼ practice. The gold standard for a definitive 
diagnosis prior to radical prostatectomy (RP) is a systematic biopsy sampling, 
usually taken in 12 cores (Bjurlin and Taneja, 2014). Some treatment modalities 
are only applicable if a patient is at low risk for biochemical recurrence of 
localized and locally advanced prostate cancer (DʼAmico et al., 1998), as de-
fined in 2021 European Association of Urology (EAU) guidelines. On the 
contrary, only palliative therapy is rational in some cases of high risk. Thus, it is 
essential to minimize the discrepancy between the histology report in a biopsy 
and the actual find in RP. However, despite the progress in biopsy sampling and 
advantages in radiology, there still is a risk of changing the grade of PCa in RP. 
A targeted biopsy is upgraded in 23.3% of cases, while systematic biopsy, still 
been primarily used, has an upgrade rate of 42.7% at RP, as shown in a recent 
meta-analysis (Goel et al., 2020). 
A question arises whether there is a way to improve the process of diagnosis 
in biopsies. There are various ways to approach the problem using new bio-
chemical, radiological, or histological methods (Alchin et al., 2015). One prac-
tical consideration, as also mentioned in the latest College of American Patho-
logists (CAP) templates, is to count stroma between cancerous foci in biopsy as 
a part of a tumor length as it better correlates with the finds in RP (Arias-Stella 
et al., 2015; Karram et al., 2011). 
Analyzing components of the tumor microenvironment, a variety of clinical 
studies suggest that reactive stromal changes can indeed provide valuable 
information and show independent prognostic potential as, for example, in the 
breast (Conklin and Keely, 2012; Olumi et al., 2000), colon (Halvorsen and 
Seim, 1989; Sis et al., 2005), and other tissues. The significance of stromal 
changes in PCa has also been described (Ayala et al., 2003; Silva et al., 2015; 
Miles et al., 2019) and correlated with Gleason grade (Osorio et al., 2019). 
Along with progression towards higher Gleason grades, the stromal phenotype 
change is accompanied by a progressive decrease in smooth muscle content and 
an increase in the proportion of myofibroblasts and cancer-associated fibro-
blasts (Cunha et al., 2003; Kiaris et al., 2004). 
In clinical practice, biopsies are taken systematically from specific sites of 
the prostate, with the location documented in the letter of the referral sent to a 
pathologist. Thus, knowing the location of the highest ISUP grade in the RP, 
biopsies from the area can be retrospectively reevaluated for possible additional 
information, such as stromogenic changes, which can be suspicious.  
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The stromogenic reaction may be challenging to quantify with only hema-
toxylin and eosin (H&E) staining. There are broadly available markers, in-
cluding immunohistochemical (IHC), that can highlight reactive changes. In the 
current manuscript, two stainings were used to highlight the microenviron-
mental changes. The first one is broadly available Massonʼs trichrome (MT) 
that serves as a good highlighter both for the simultaneous analysis of smooth 
muscle and collagen change in PCa. The second one is Fanconi-anemia comple-
mentation group M (FANCM) immunohistochemistry marker – the DNA 
reparation complex protein expressed in the normal prostate (Kasak et al., 
2018). It is relatively new, and there are only a few manuscripts that evaluate its 
significance in the stroma with no systematic evaluation in the prostate. 
Still, even with additional staining, stromal changes are usually evaluated in 
a less precise qualitative way, combined into groups, which can lose some 
interconnections and thus is inappropriate for the description of new markers, 
such as FANCM. At the same time, digital slide easily allows accurate and fast 
analysis meaning that digital pathology (DP) can be of significant assistance. 
DP is a digitalization process of histological slides using specialized scan-
ning machines with a further computer-assisted analysis of the whole-slide 
images (WSI), while microscope cameras only provide small fields of view. 
Following the quantification of immunohistochemical and -fluorescence 
markers (cellular level), which can now be automatically evaluated by machine 
learning algorithms (Hamilton et al., 2014), the main focus for a couple of last 
years is on automatically completed tissue analysis and diagnosis. In combi-
nation with machine learning (ML) and modern hardware, the opportunity for a 
computer-assisted diagnosis to become a routine is very realistic. Nevertheless, 
despite the claims that ML can already outperform pathologists in definitive 
diagnoses, such as Gleason grading (Arvaniti et al., 2018; Bulten et al., 2020), 
there is a list of challenges to overcome before ML can be routinely applied 
(Madabhushi and Lee, 2016). Among these are the subjective opinion of patho-
logists during model training and extreme sensitivity to the slide quality, 
meaning if the trained model is used in different laboratory settings, results can 
be unsatisfactory. 
While still new and somewhat unreliable for a pathologist, ML could already 
find its place in daily routine. An example of practical application is a creation 
of a simple model distinguishing the prostateʼs main histological components, 
such as fibromuscular stroma, nerves, glands, and fat. Such a model would 
allow the performance of further independent and automated quantification of 
component changes- MT and FANCM intensity. Also, it could be applied to a 
screen for features essential to report, yet sometimes tricky to find: for example, 
extraprostatic extension (EPE) and perineural invasion (PNI). These changes are 
not so diverse and primal for a diagnosis as cancer grading but still have a 
critical value. Moreover, it could help to separate the glandular component with 
further analysis of epithelial markers, such as Ki67. 
Despite the fact that novel solutions for DP analysis, including the open-
source ones, are constantly developed, by the time of the start of doctoral 
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studies, there were no programs for simple annotation, creation, and augmen-
tation of the dataset, training, and visualization of the result, to experience ML 
from scratch. 
The work aims to quantify and evaluate the diagnostic significance of micro-
environmental changes around different Gleason grades by creating a computa-
tional imitation of pathologistsʼ work. The machine should distinguish and 
highlight histological components and assess the amount of nuclear (Ki67) and 
cytoplasmic staining, thus covering almost all essential diagnostic features 
except cancer differentiation. The manuscript should also serve as a manual for 
everyone willing to start with DP and ML in pathology and to encourage staff 




2. REVIEW OF LITERATURE 
2.1 Histology of prostate 
The histological structure of the prostate is usually described in three or four 
zones (McNeal, 1984), which are essential to distinguish in the context of the 
current manuscript: 
1. The peripheral zone makes about 70% of prostatic volume, from apex 
posteriorly beneath the capsule to base, surrounding transition, and central 
zones. Fibromuscular stroma is relatively loose with widely spaced smooth 
muscle bundles, and glandular complexity is moderate. About 70–80% of 
prostatic cancers originate from this zone (Reissigl et al., 1997). 
2. The transition zone is about 5% of the prostatic volume surrounding the 
proximal urethra. It contains moderately compact bundles of smooth 
muscle. It is the main site of nodular prostatic hyperplasia. Prostate cancer 
arises in the transition zone in approximately 10–25% of cases (Lee et al., 
2015). 
3. The central zone is nearly 25% of prostatic volume. It surrounds the tran-
sition zone to the angle of the urethra to the bladder base and the ejaculatory 
ducts. It is a site of 2.5–5% of prostate cancer (Cohen et al., 2008). The 
ducts are large and irregular; glands are complex, frequently with papillary 
infoldings. The stroma is dense. 
4. Anterior fibromuscular zone: not always considered as a zone, sometimes 
viewed as a part of the peripheral zone, lacks the glandular components. 
 
Most of the glandular tissue is found in the peripheral and central zones. Stroma 
is the densest in the central zone, the least dense in the peripheral zone. The 
study samples used during the research were from the peripheral zone. 
 
 
2.2 Prostate adenocarcinoma 
2.2.1 Epidemiology of PCa 
Following lung cancer, prostate cancer is the second most frequent malignancy 
in men worldwide, counting 1,276,106 new cases and causing 358,989 deaths 
(3.8% of all deaths caused by cancer in men) in 2018 (Bray et al., 2018). Pros-
tate cancer incidence rates are highly variable worldwide for reasons not fully 
understood. One possible explanation is dependence on PSA screening pro-
grams (Quinn et al., 2002, Patasius et al., 2019). Around 20–40% of the PCa 
diagnoses in Europe and the USA could be due to overdiagnosis through 
extensive PSA testing (Draisma et al., 2009). 
The age-standardized rate in Europe is 62.1 per 100,000 people, according to 
GLOBOCAN 2018 (Rawla et al., 2019), and is the most frequently diagnosed 
cancer among men, accounting for 24% of all new cancers in 2018. Further-
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more, the incidence rates in European countries continue to increase slightly 
(Mottet et al., 2017). Although prostate cancer incidence rates are high, most 
prostate cancer cases are detected when the cancer is confined to within the 
prostate. 
The international mortality rates also vary considerably, being 10.1 per 
100,000 people in Western Europe, and have been steadily declining for the past 
years in most western countries (Taitt et al., 2018). Although not fully clear, it 
may reflect early detection and improved treatment (Collin et al., 2008; Etzioni 
et al., 2008). 
According to 2017 data of the Estonian National Institute for Health 
Development, PCa was diagnosed in 1113 cases, making 25.2% of all diag-
nosed malignancies among men. In the age group of 60–79, every eight will 
struggle with illness. Currently, Estonia has no official prostate cancer screening 
program, although, in clinical practice, physicians routinely offer the test to 
middle-aged and older men. According to the study covering patients from 
1995–2014 (Innos et al., 2017), the overall 5-year relative survival ratio in-
creased from 58% to 90% over the study period; survival increased conside-
rably for all stages. This corresponds to general European trends. 
After PCa is suspected (pathological PSA, digital rectal examination, 




2.2.2 Histological stains used in PCa diagnosis 
2.2.2.1 Overview of the main stains 
Central and usually the only stain used in PCa diagnosis is H&E. At the same 
time, there is a growing number of literature analyzing the role of additional 
staining for the confirmation of the diagnosis and prognosis. In addition to 
H&E, the most frequent stains include: 
1.  The “triple antibody cocktail” is the most widely used additional stain (Ross 
et al., 2020). It amplifies the atypical glandular component and shows the 
presence or lack of myoepithelial cells. It consists of: 
1.1 Alpha-methylacyl-CoA racemase 
1.2 p63  
1.3 High Molecular Weight Cytokeratin 
2.  PSA – sensitive and specific for prostatic tissue and adenocarcinoma of pros-
tatic origin. Loss of PSA stain correlates to poor differentiation and poor 
prognosis (Bonk et al., 2019). 
3.  Chromogranin, synaptophysin, CD56. The markers are used for neuroendo-
crine cells, frequently looking similar to Gleason 5 patter (Fine, 2018). 
4.  Androgen for luminal cells and seminal vesicles. 
5.  34 beta E12 for basal cells. 
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6. Paired-box gene 8 (PAX8). It helps to differentiate urothelial carcinoma 
variants and adenocarcinoma of the urinary bladder or prostate (PAX8 nega-
tive) (Tong et al., 2008). 
Additionally, markers as Ki-67, p53, PTEN, MYC, and ERG are actively used 
despite the lack of validation (Carneiro et al., 2018). 
As can be seen, the markers cover exclusively glandular components of PCa, 
although PCa is no longer viewed as a disease of abnormally proliferating epi-
thelial cells but rather as affecting the complex interactions between the epi-
thelial cell and the surrounding microenvironment (Chiarugi et al., 2014, Guo et 
al., 2021). Thus additional stains for microenvironmental changes are gaining 
more and more attention. 
 
 
2.2.2.2 Ki67 in PCa 
Ki67 is a nuclear protein associated with cell proliferation (Scholzen and 
Gerdes, 2000). The staining is not frequently used in PCa, although studies dis-
play a strong correlation with Gleason grade, association with stage, seminal 
vesicle invasion, and extracapsular extension (Tretiakova et al., 2016; Verma et 
al., 2015). It has a significant prognostic value, and the importance is as well 
shown in the prediction of recurrence in prostate biopsies (Fisher et al., 2013; 
Kammerer-Jacquet et al., 2019). It may also help to distinguish such chal-
lenging samples as, for example, high-grade prostatic intraepithelial neoplasia 
and intraductal carcinoma, both frequently displaying Alpha-methyacyl-CoA 
racemase, p63, and high molecular weight cytokeratin complex positivity. 
Recent studies show that a combinatory PSA/Ki67 immunoreactivity score 
may help to subdivide prostate cancers into groups of different clinical out-
comes (Hammarsten et al., 2019). 
As the aim of the manuscript is not only to focus on the prostate but provide 
an applicatory solution to rationalize the time of practitioners compelled to 
counting positive cells, Ki67, being one of the most commonly used IHC stains 




2.2.3 Histological grading of prostate adenocarcinoma 
In 1966, Dr. Donald Gleason introduced the method for predicting the outcome 
in prostate cancer by distinguishing five histological grades based on glandular 
architecture and microscopic appearance using a 4x – 10x objective magni-
fication (Gleason, 1966). 
With some essential changes, the general principle of the method is still used 
today. The Gleason grading system is used in all prostate adenocarcinomas, 
except those with treatment effects (for example, after androgen withdrawal or 
radiation therapy) (Humphrey et al., 2015). 
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It sums two patterns (grades), primary (most predominant in terms of the 
surface area of involvement) and secondary, into the Gleason score. If no 
secondary Gleason grade exists, the primary Gleason grade is doubled to arrive 
at a Gleason score. Gleason sum is slightly different in RP and biopsy. 
In RP: 
• The primary pattern is assigned to the dominant pattern of the tumor 
(>50% of the total pattern. 
• The secondary pattern is assigned to the next most frequent pattern 
(50%<X>5%) 
• The tertiary pattern- is frequently found in RP and is not incorporated 
into the final sum if < 5%. If Gleason pattern 5 is >5% and constitutes the 




• The most prevalent pattern is graded as primary 
• Any amount of the worst pattern is graded as secondary 
 
The grading rules were modified by the ISUP and WHO in 2005 (Epstein et al., 
2005), 2014 and 2019 (van Leenders et al. 2019). 
Since 2014, a simplified patient-centered grading system composed of 5 
prognostic Grade Groups (G) is adopted and validated by biochemical recur-
rence hazards ratios on cases from 5 academic centers (Epstein et al., 2015). 
This grouping is similar to PI-RADS and denotes prognostically distinct strati-
fication. Currently, the Grade Groups are as follows: 
G1: Gleason score 3+3=6  
G2: Gleason score 3+4=7  
G3: Gleason score 4+3=7 
G4: Gleason score 8 (4+4=8, 3+5=8, 5+3=8) 
G5: Gleason score ≥ 9 (4+5=9, 5+4=9, 5+5=10) 
 
Before choosing the treatment option, the standard for definitive diagnosis is a 
systematic biopsy sampling, usually taken in 12 cores (Bjurlin and Taneja, 
2014). Considering prostate-specific antigen (PSA), radiology, and biopsy 
histology, the risk for biochemical recurrence of localized and locally advanced 
prostate cancer is stratified as follows: low, intermediate, or high risk, 
corresponding to International Society of Urological Pathology (ISUP) Grade 1 
(G1), G2 and ≥G3. This makes the basis for a treatment plan: whether the 
patient is suitable for active surveillance or watchful waiting, can the nerve-
sparing prostatectomy be performed, how to behave in the case of a negative 
biopsy sampling with a rising PSA, etc. Some treatment modalities are only 
applicable if a patient is of low risk, with active surveillance or watchful waiting 
as an example (Lu-Yao et al., 2009). Recognition of tumor features, such as 
multifocality, also provides critical prognostic information regarding tumor 
16 
behavior (Epstein et al., 2005). Thus, it is essential to minimize the discrepancy 
between the histology report in a biopsy and the RPʼs actual find. 90–95% of 
prostate cancer is of acinar type (Shah and Zhou, 2019), which is primarily 
handled in current research. 
 
 
2.2.4 Biopsy and RP Concordance 
Despite the rapid progress in biopsy sampling and advantages in radiology (as 
MRI- targeted procedure), there is still a risk of changing the grade of PCa in 
RP. A targeted biopsy is upgraded 23.3% of the time, while systematic biopsy, 
still been primarily used, has an upgrade rate of 42.7% at RP, as shown in a 
recent meta-analysis (Goel et al., 2020). Before the 2005 ISUP consensus, the 
rate was even lower (Arias-Stella et al., 2015). The downgrade, which is 
clinically not as essential but should be considered, can also happen in 6–36% 
(Fukagai et al., 2001; Ozok et al., 2010; Van Praet et al., 2014). Different 
factors, as PSA density (Sfoungaristos et al., 2013; Sfoungaristos and Peri-
menis, 2013; Vellekoop et al., 2014), age (Epstein et al., 2012; Seisen et al., 
2015), prostate volume, and even obesity (Truong et al., 2013) were tested for 
possible predictive value; none is used clinically so far. 
Additional information, which could be attained from biopsy samples, gains 
more and more attention. As the applied markers for cancerous epithelial cells 
may behave insufficiently in a clinical setting, an idea of evaluating the signi-
ficance of microenvironmental changes as an always-available component has 
emerged (Planche et al., 2011; Boufaied et al., 2019). 
 
 
2.3 Stromal changes in carcinomas and  
their diagnostic value 
2.3.1 General aspects 
Cancerous epithelial complexes are known to recruit and transform normal cells 
into reactive tumor stroma, which plays complex roles in promoting tumor 
progression. Along with the progression towards higher Gleason grades, the 
phenotype change into a reactive stroma is accompanied by a progressive de-
crease in smooth muscle content and an increase in the proportion of myofibro-
blasts and cancer-associated fibroblasts (Cunha et al., 2003; Kiaris et al., 2004; 
Olumi et al., 2000), accompanied by the corresponding decrease in α-smooth 
muscle actin expression (Ayala et al., 2003). Myofibroblasts in a transformed 
tumor stroma synthesize extracellular matrix proteoglycans and metallo-
proteinases, some of which are tested as potential histological stromal markers 
in PCa. For example, a gradual increase of asporin expression in PCa stroma is 
associated with the disease progression (Hurley et al., 2016; Rochette et al., 
2017). Increased versican expression in PCa stroma has been correlated with a 
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patientʼs poor survival. The stromal staining intensity of decorin has been found 
to decrease in malignant areas, but no grade-dependent gradual changes or 
correlation with survival were reported (Henke et al., 2012; Suhovskih et al., 
2013). Based on a meta-analysis of the literature, matrix metalloproteinase-2 
expression is significantly associated with PCa (Xie et al., 2016). 
Stromal changes are thought to have a crucial role in cancer invasion, meta-
stasizing, and castrate- resistance (Eiro et al., 2017; Langley and Fidler, 2011; 
Yang et al., 2017). It is claimed that the stromogenic reaction found in biopsy is 
a predictor of further cancer recurrence (Kweldam et al., 2018). Stromal-
epithelial crosstalk to prostate cancer initiation and progression provides the 
impetus for combinatorial microenvironment-targeting strategies (Karlou et al., 
2010; Valkenburg et al., 2018). 
Stromal changes are challenging to quantify in rational numbers using a 
microscope, as, for example, in H&E, both muscles and collagen may have 
similar staining and architectonics, distinguishable only for an experienced 
pathologist. In order to find a diagnostically significant pattern between stroma-
gland cross-reaction, especially in terms of new markers, the evaluation of such 
should be precise.  
To evaluate the stromogenic reaction in PCa and demonstrate the advantages 
of DP for this purpose, two stainings were used: broadly used Massonʼs tri-
chrome (MT) and, relatively novel in the prostate, Fanconi Anemia Comple-
mentation Group M (FANCM) antibody. 
 
 
2.3.2 Massonʼs trichrome 
MT is three-color staining: most recipes produce red keratin and muscle fibers, 
blue or green collagen and bone, light red or pink cytoplasm, and dark brown to 
black cell nuclei. In the context of the prostate allowing simultaneous analysis 
of smooth muscle and collagen, an old and largely used marker, MT is a good 
highlighter of stromogenic reaction and a good alternative to vimentin or α- 
smooth muscle actin to quantify such change. Along with other carcinomas, MT 
is also suggested to be stained in PCa as an additional diagnostic marker 
(Krušlin et al., 2015; Tuxhorn et al., 2002). In the manuscript, the hypothesis of 
a gradual increase of collagen type I, proportional to the ISUP grade and its 
predictive value, is tested. 
 
 
2.3.3 Fanconi Anemia Complementation Group M 
FANCM displays DNA binding against fork structures and an ATPase activity 
associated with DNA branch migration (Coulthard et al., 2013). DNA repara-
tion complex proteins perform a protective role by stabilizing DNA double-
stranded breaks and repairing DNA interstrand crosslinks in the process of 
homologous recombination (HR) (Ceccaldi et al., 2016), and are an emerging 
target in cancer therapy (OʼRourke et al., 2019; Pan et al., 2017).  
18 
Bi-allelic pathogenic alterations, affecting HR-related genes, such as BRCA1, 
BRCA2, are associated with HR deficiency and are identified in epithelial com-
partments of various cancer types, including breast, ovaries, and prostate (Riaz 
et al., 2017), but no reports on their expression in tumor stroma have been 
published during a period when this manuscript was prepared. Among HR 
pathway DNA reparation genes, the Fanconi anemia complementation group M 
(FANCM) encodes a DNA-dependent ATPase critical in DNA repair, anti-
crossover activity, and prevention of chromosomal breakage in mitosis and 
meiosis (Basbous and Constantinou, 2019; Tsui and Crismani, 2019; Xue et al., 
2015; Yan et al., 2010). There are numerous reports of families with segregating 
FANCM mutations and clustering of various cancer types, such as breast and 
ovarian cancers (Bogliolo et al., 2018; Catucci et al., 2018; Nguyen-Dumont et 
al., 2018; Nikolaidi et al., 2019). The evidence has led to the hypothesis that an 
insufficient level of the FANCM expression may represent a novel candidate 
marker for histological evaluation of prostate cancer risk and progression. 
It is shown that the stroma of the normal prostate displays intense staining of 
the FANCM protein (Kasak et al., 2018). The current study is the first report on 





3. DIGITAL PATHOLOGY 
3.1 General aspects 
To simplify the understanding of the current state of DP, two parts should be 
distinguished. 
The first is an image acquisition subsystem (scanning device) and a worksta-
tion environment with a WSI viewer with basic tools: manual measurements, 
annotations, simple manipulations with the image, and telepathology. Gaining 
approval in the United States and European Union (García-Rojo et al., 2019) DP 
is evolving and growing steadily, vividly demonstrating all its advantages during 
COVID-19 pandemics (Browning et al., 2021; Cimadamore et al., 2020). The 
annual growth for DP in Europe and the US is expected to be 8.2% for the next 
five years, according to the recent Frost & Sullivanʼs analysis (https://frost.com). 
In Estonia, the use of DP for routine diagnostics was first started at the East-
Tallinn Central hospital pathology department in September 2019 when Pan-
noramic 250 flash III by 3DHistech was installed: a mid-range device with a 
250 slide capacity and 20x or 40x optical magnification. The device success-
fully processes a daily load of approximately 500 slides and is actively used by 
eight pathologists of the department, based on the authorʼs observation. Most of 
the digitalization for this manuscript is performed mainly on this station. 
Despite the high diversity of manufacturers, the scanning devices evolve 
rapidly and generally synchronously, mainly varying on slide capacity, optical 
magnification, and a short list of additional features, such as z-stack, immuno-
fluorescence, immersion (Cui and Zhang, 2021; Pantanowitz et al., 2018), thus 
are not reviewed in this work. The resulting image has a similar pyramid form 
with a small thumbnail on the top, and a high-resolution picture on the bottom 
layer, providing a high range of field of views, not accessible by the micro-
scope. Digitalized images are a basis for the advanced analysis of DP. 
 
 
3.2 Advanced analysis in DP 
The manuscript focuses on the advanced possibilities linked with DP. The 
theme is one of the most prominent points of interest in modern pathology. As 
the slide is digitalized, computer assistance of varying complexity, starting from 
the fundamental image analysis such as color-thresholding and ending with 
automatic diagnosis via machine learning algorithms, can be applied. In terms 
of the shortage of pathologists, this could be a significant support to diagnostics. 
Following quantification of immunohistochemical and immunofluorescence 
markers (cellular level), which now can be reliably performed automatically 
(Hamilton et al., 2014), the main focus for a couple of last years is on an auto-
mated tissue analysis. 
Despite the promising results in automatic diagnoses, such as Gleason 
grading that can reportedly outperform pathologists (Arvaniti et al., 2018; 
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Bulten et al., 2020), it is currently facing a list of challenges, making it difficult 
to apply routinely (Madabhushi and Lee, 2016). Among these challenges are the 
subjective opinion of pathologists during model training and extreme sensitivity 
to the quality of the slide, meaning that if the trained model is used in settings of 
a different lab, results can be unsatisfactory. 
Nevertheless, obstacles seem to be temporary as labs become more stan-
dardized and the augmentation possibilities of the image dataset evolve. The 
new trend in pathology induced the rapid development of both commercial and 
open-source solutions for advanced analysis. 
 
 
3.2.1 Open-source solutions for bioimage analysis 
As within the frame of the current study, there was no way nor aim to objec-
tively evaluate the quality of all the commercial solutions; all the provided tools 
are based on open-source algorithms and freeware. 
The list of libraries for bioimage analysis is enormous and constantly ex-
panding by adding utilities of particular functions, as can be seen, for example, 
in DigitalSlideArchive repository: https://github.com/DigitalSlideArchive 
It means that a programmer can combine a tool satisfying even the most 
specific needs of a pathologist. 
The list of main libraries, that make a core for WSI analysis: 
1. OpenSlide (Goode et al., 2013) – a vendor-neutral library to work with the 
main WSI formats: 
1. Aperio (.svs, .tif) 
2. Hamamatsu (.vms, .vmu, .ndpi) 
3. Leica (.scn) 
4. MIRAX (.mrxs) 
5. Philips (.tiff) 
6. Sakura (.svslide) 
7. Ventana (.bif, .tif) 
8. Generic tiled TIFF (.tif) 
2. Bio-Formats (Linkert et al., 2010) – the solution for reading proprietary 
microscopy image data and metadata. 
3. OpenCV (https://opencv.org/) – a set of programming functions mainly 
aimed at real-time computer vision. 
4. Scikit-learn (https://scikit-learn.org/) – a Python machine learning library. 
5. TensorFlow (https://www.tensorflow.org/) – a library for machine learning 
by Google that is easily combinable with Google Drive and Google Colab. 
 
The most popular ready-to-work programs are: 
1. ImageJ (Schneider et al., 2012). Released in 1997, it is the best known open-
source software for biomedical image analysis with a wide variety of plugins 
and manuals that can display, edit and perform the analysis of varying 
complexity as well as save the majority of image formats; with the exception 
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of some WSI (as .mrxs), the format is essential for the current thesis. It 
requires significant modifications to cover the needs of the modern DP fully.  
2. QuPath (Bankhead et al., 2017). A powerful open-source OpenSlide and 
OpenCV-based desktop bioimage analysis software. The only solutions in 
the list which initially were oriented to work with WSI images. It has 
flexible biomarker evaluation tools, provides batch-processing and scripting 
functionality, and allows to development and share of new algorithms to 
analyze complex tissue images. The image analysis is partially performed by 
exporting the image area to ImageJ. It cannot generate datasets and run third-
party trained models. 
3. CellProfiler (Lamprecht et al., 2007) enables a user without skills in pro-
gramming to measure the phenotype from the thousands of images simulta-
neously; lacks a fully functional WSI support. 
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4. SUMMARY OF THE LITERATURE REVIEW 
PCa is one of the most frequent malignancy diagnoses and makes a significant 
part of pathologistsʼ work. Despite the recent improvements, the discrepancy in 
histology reports between the biopsy and RP is still high. This can potentially 
lead to inappropriate prognosis and treatment modalities. One practical conside-
ration to improve the concordance of diagnosis is to quantify microenviron-
mental changes around the cancerous glands. Stroma is nearly always found in 
all biopsies; stromogenic reaction has already been proven to be a significant 
prognostic and diagnostic feature in different carcinomas as breast or colon and 
is actively studied in PCa. 
Of two selected stainings to describe the stromogenic reaction, one is well 
known Masson`s trichrome, with controversies addressing its additional value 
in PCa diagnosis. The second one is relatively novel FANCM, which was not 
previously systematically evaluated in the prostate. 
Precise quantification of the microenvironmental changes even highlighted 
with additional markers, may be challenging and time-consuming if performed 
with routine microscopy. At the same time, image analysis programs can per-
form color quantification objectively. 
Machine learning algorithms can already do tissue segmentation at a high 
precision rate. 
With a combination of digital pathology solutions, machine learning, and 
bioimage analysis algorithms, the stromogenic reaction can theoretically be 
evaluated in a semi- or fully automatic manner. The result should be quick and 




5. AIMS OF THE STUDY 
The main aim of the work is to quantify and evaluate the diagnostic significance 
of carcinoma-associated microenvironmental changes around different Gleason 
grades and the applicatory use in biopsies.  
This task first requires resolving a more general methodological issue as the 
development of a DP solution that is easy to use, accurate, and which working 
principle would mimic the pathologistʼs routine diagnostic process when 
working with a light microscope. 
Specific tasks in the logical chronology to perform an objective biopsy ana-
lysis are as follows: 
1. Create a WSI oriented open-source set of tools allowing to perform: 
1.1.  Fundamental color analysis (K-means, color thresholding) in the region 
of interest (ROI). 
1.2.  Quantification of diaminobenzidine (DAB) positive and negative cells 
in the ROI 
1.2.1. Using provided tools, evaluate DAB positive cell counting preci-
sion by quantifying Ki67 (as one of the most popular IHC 
markers)  in PCa-s of different ISUP grades. 
1.3. Generation of image dataset for ML from digital slides. 
1.4. Visualization and validation of the trained model. 
2. Create and validate a multiclass model, segmenting the prostate into five 
components – glands, stroma, nerves, fat, gaps for further independent ana-
lysis. 
3. Using provided software tools, quantify stromal changes correlation with 
ISUP grade in MT and FANCM stained samples: 
3.1. Systematically evaluate FANCM staining in the prostate. 
3.2. In RP samples, objectively evaluate the significance of PCa associated 
microenvironmental changes and determine the rationality of further 
studies in the limited volume of biopsies. 
3.3. In biopsies, to evaluate the possibilities of practical diagnostic applica-
tion of PCa associated microenvironmental changes.  
 
The methodology is expected to be somewhat universal and serve as a manual 





6. MATERIALS AND METHODS 
6.1 Ethics 
The study was approved by the Ethics Review Committee of Human Research 
of Tallinn, Estonia (approval No 2173, issued on 12 May 2017) and the Esto-
nian Data Inspection Protectorate (approval No 2.2.-1/17/50, issued on 19 Dec 
2017). The nature of the study is retrospective. Patients remain anonymous. 
 
 
6.2 General workflow 
The methodology of the work resembles the routine workflow of a pathologist: 
studying histology on an H&E stained glass, distinguishing learned information 
on a new H&E slide, finding the corresponding region on slides with other 
stains, and analyzing the area. The main steps of the methodology are provided 




Figure 1. The main steps of the methodology. 




The material for the studies was acquired from East Tallinn Central Hospital 
from the period of 2007–2010. The inclusion criteria were a biopsy and RP 
performed at the same hospital to maintain the standard of the material and a 
pathology report. Overall, consecutive samples from 385 patients were ana-
lyzed, with a mean age of 65 (40–80) years at prostatectomy (Dzaparidze et al., 
2021). The ISUP grade was reevaluated in both biopsies and RP according to 
2016 WHO criteria. The distribution of patients according to ISUP grade in RP 
and biopsy is provided in Table 1. 
 
 
Table 1. Distribution of patients according to ISUP grade in biopsy and RP. 
 
  Biopsy G 
  G1 G2 G3 G4 G5 
RP G 
G1 136 2    
G2 59 50 12 2  
G3 16 27 28 6 2 
G4 7 2 9 14 1 
G5  1 1 6 4 
(abbreviations: G- grade group, RP-Radical prostatectomy) 
  
 
In 232 cases (60%), biopsy and RP ISUP grades were equal, upgraded in 128 
(34%) RP, and downgraded in 25 (6%) cases. Among upgraded samples, the 
most frequent was, as expected, in G1 carcinomas in 82 patients. G2 was up-
graded in 30, G3 in 10, and G4 in 6 cases. 
Of 385 patients, 288 were in stage pT2, 94 pT3, and 3 pT4. Only five had 
metastases in regional lymph nodes (pN1). No patients with distant metastases 
were included. 
In addition to the analytical set, 25 RP samples (5 per each grade group) 
were acquired from the West Tallinn Central Hospital to increase the diversity 
and minimize the batch effect in machine learning. All the patients were pT2 
pN0 cM0. 
For control, 11 autopsy samples were harvested. The mean age of the pa-
tients was 67 years (47- 89) with other causes of death than cancer and no pre-
viously diagnosed prostatic diseases. The majority of deaths had been caused by 
cardiovascular diseases (9/11). An autopsy was performed within 24 hours after 
death to minimize autolysis effects. The post mortem diagnoses are listed in 
Table 2. 
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Table 2. Information on autopsy controls. 
Patient At death (yrs) ICD 10 Specification 
1 83 I71 Aortic aneurysm and dissection 
2 83 K85  Acute pancreatitis 
3 54 I25 Chronic ischemic heart disease  
4 69 I71 Aortic aneurysm and dissection 
5 82 I13 Hypertensive heart and chronic kidney disease 
6 57 I25 Chronic ischemic heart disease  
7 89 I25 Chronic ischemic heart disease  
8 70 T84 Complications of internal orthopedic prosthetic devices 
9 47 I11 Hypertensive heart disease with heart failure 
10 47 I42 Cardiomyopathy  
11 53 I42 Cardiomyopathy  
 
 
6.4 Staining protocols 
H&E was stained using validated East-Tallinn Central Hospital protocols. 
MT, FANCM, and Ki67 stained glasses were prepared from the same paraf-
fin block. The staining protocols for MT and Ki67 are frequently used and can 
be found based on the catalog number. 
1. For MT, Trichrome III Green Staining Kit (catalog n.r 860-031), a modifica-
tion of Massonʼs Trichrome Stain by Ventana with Bouinʼs Solution appli- 
cation to intensify the final coloration; all deparaffinization and staining pro- 
cesses were carried out in Benchmark Special Stains by Ventana (Arizona, 
USA). 
2. For Ki67 nuclear stain (catalog n.r 790-4286, rabbit monoclonal antibody 
(IgG)), all chemicals used were the products of Ventana), all deparaffini-
zation and staining processes were carried out in BenchMark Ultra auto-
mated stainer (Ventana). 
3. FANCM in the prostate was not previously systematically evaluated in the 
prostate, only in single non-cancerous samples (Kasak et al., 2018). All 
deparaffinization and staining processes were carried out in BenchMark 
Ultra automated stainer (Ventana); all chemicals used were the products of 
Ventana. The conditions and solutions used in IHC of the FANCM protein 
were as follows: deparaffinization of tissue sections with EZ Prep solution 
pH 8.4 at 72°C, heat pretreatment for antigen retrieval in Tris/ Borate/ 
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EDTA buffered Cell Conditioning 1 (CC1) solution pH 8.4 at 100°C for 32 
min and incubation with anti-human FANCM primary antibody (aa 1507-
1679; x; CV5.1; Novus Biologicals, Abingdon, UK) at a dilution of 1:2000 
for 24 min at 37°C. Primary antibody concentrations for the detection of the 
FANCM protein had been titrated to gain optimal staining of stromal com-
partments. During the optimization of the protocol, dilutions of 1:100 and 
1:500 were also tested, in which weak positivity of FANCM staining was 
also detected in the glandular compartments. At these higher dilutions, the 
stromal compartment became overstained and indistinguishable from the 
background. The slides were incubated with secondary HQ Linker anti-
bodies, followed by the application of HRP Multimer and the visualization 
via incubation with the OptiView DAB Kit, each step lasting 8 min. Tris-
based buffer pH= 7.6–7.8 was used for the incubation of antibodies and the 
washing steps. Finally, the slides were counterstained with Hematoxylin II 
and post-counterstained with Bluing Reagent for 8 min each. Before moun-
ting, slides were dehydrated through 70%, 96%, and 100% alcohols, cleared 
with xylene and covered using the permanent LCS- Liquid Coverslip moun-
ting media and cover glass (Dzaparidze et al., 2020). 
 
 
6.5 Slide digitalization 
All analyzed slides were scanned using a 3DHistech Pannoramic Flash III 250 
scanner (3DHistech, Budapest, Hungary) at a 20x magnification (resolution 
0.24 μm / pixel, .mrxs format). Similarly to routine work, the magnification de-
pends on the expected outcome: if the predicted outcome is on a cellular level, 
40x or higher might be preferred. Otherwise, due to a drastic increase in the size 
of the slide, it is somewhat irrational. 
The average size of a RP slide at mentioned resolution was 3.21 Gb, a 
biopsy – 0.78 Gb. 
 
6.6 Pathadin 
The software created for a digital analysis was named Pathadin (Pathology + 
Paladin) (Dzaparidze et al., 2020). The source code, original datasets used in 
the study, slicing, and training pipelines, as well as trained models, are provided 
at the open repository: https://gitlab.com/Digipathology/Pathadin 
https://github.com/geodza/Pathadin 
Minimum system requirements for adequate experience for provided bina-
ries include monitor resolution of 1280 × 720, operation system Windows 7 SP1 
or newer, CPU Intel DualCore, RAM 4 GB. 
Among Java solutions, Pathadin is Python 3.6 software built with PyQT5 
graphical user interface (GUI). Pathadin is based on the OpenSlide library. 
Central analytic libraries include Keras, Skimage/ Sklearn, and Histomics TK 


















































































Pathadin is oriented to work with digital slides but includes all the main image 
formats. The concept of Pathadin differs from other alternatives listed pre-
viously. In contrast to unitary solutions, which require rather powerful machi-
nes, it is a combinatory set of tools, where each part can be modified separately. 
Such an approach should give a better understanding of functional elements of 
modern computer-assisted image analysis, make the program more flexible in 
the context of updates, and try different machine learning algorithms. 
Pathadin performs routine tasks as color thresholding and K- means, signi-
ficant for stroma quantification, are inside the software. 
Currently, Pathadin provides the basic set of tools to begin with modern 
digital pathology: 
1. Intuitive GUI: the application includes both basic image analysis algorithms, 
such as color thresholding, and advanced modules for IHC quantification by 
Histomics serving as an example of an integrated solution.  
2. An advanced tool for slicing digital slides – used for a simple image dataset 
generation and augmentation for machine learning. 
3. Reproducible example/pipeline for dataset generation and model training (U-
net) with further integration to Pathadin. 
4. All the generated data can be easily exported into a table for further analysis 
in statistical software. 
Machine learning modelsʼ training is computationally heavy and excessively 
dynamic and requires rather powerful machines, thus frequently irrationally to 
be enclosed by GUI. 
In the manuscript, the example of U-net training was based on Pathadin 
generated datasets and performed separately from GUI. The trained model was 
then imported back to the software. 
All the analysis, model testing, and validation were performed with the 
following systems: Core i7-9760H, 2.6 GHz, 16 GB DDR4-2666 SDRAM / 
Ryzen 7 2700, 3.2 GHz, 16 GB DDR4-2066 SDRAM. 
 
 
6.7 Multiclass model training and validation 
The next step after the release of Pathadin was the creation of a working ML 
model.  
The creation of a model includes the following steps: 
1.  Formulation of the expected outcome. 
2. Creation of a dataset — a set of images for machine learning: 
2.1  Gathering of samples for training and validation. 
2.2  Annotation of regions of interest (something one wants to teach) to 
create a dataset for training and further validation. 
3.  Selection of an appropriate ML algorithm for training. 
4.  Testing and validation of the model. 
If the outcome is unsatisfactory, additional samples, annotations, or choosing a 
different model might be required.  
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6.7.1 Selecting samples for the ML 
Results of training and model universality are sensitive to the quality of samples. 
Homogenous samples gathered from the same lab during a short period of time 
may result in a batch effect- artificial sources of variation (systematically too 
light or uneven eosin, specific to one lab, etc.), which may confound the dis-
covery of actual explanatory variables from data (Schmitt et al., 2021). There 
are computational methods for controlling the quality and increasing the hetero-
geneity of images (Janowczyk et al., 2019), but one of the most reliable 
methods for reducing the batch effect is by gathering samples from different 
labs. For the current study, the material was provided by the pathology depart-
ments of the East and West Tallinn Central hospitals. Focusing on the sufficient 
level of variation, samples of different quality were acquired, including the old 
ones with such artifacts as uneven H&E staining and thickness and stretches. 
The slides with diverse histological patterns in terms of pathology were pre-
ferred. Overall, H&E stained samples of 73 patients, including 38 RP and 35 
biopsies, were harvested and divided into training and validation groups. The 
number of samples is the result of repetitive training and testing of the model, as 
described further. 
RPʼs inclusion criterion was the presence of all five components: stroma, 
glands, nerves/ganglia, fat, and empty areas (as inside glands). All slides had a 
portion of non-cancerous regions and PNI of different extensions. Eleven had 
the presence of benign stroma and glandular hyperplasia. All ISUP grades, with 
the exception of the patterns, were covered. Inclusion criteria for biopsies were 
less strict due to the limited size of the tissue: all slides had stromal and 
glandular components, empty areas, and, most importantly, nerves/ganglia as 
assumably the most challenging, thus a component of the initial focus. 
If microarray samples are used for training tissue, the annotation of the 
whole image due to its small size is appropriate. In the case of RP, only some 
areas are selected since it is better to get more RP samples than to increase the 
number of annotations on the sample. All slides were partially annotated to the 





6.7.2 Dataset generation 
For training (TRG), 38 slides, including 13 RP and 25 biopsy samples, were 
annotated with 1166 areas of different sizes, with the areas further sliced into 
smaller patches to create a dataset for machine learning. Depending on the ex-
pected outcome, variation in the patch size and magnification may result in 
different effects. In the manuscript, the magnification levels of 5x, 10x, and 20x 
were alternately tested with 256×256, 512×512, and 1024×1024 px patches. The 
optimal model appeared to be 256×256 px patches magnified to 5x since, for 
example, an extremely high magnification or small patches could not dis-
tinguish fat from empty gaps.  
Of 1166 annotations, 114189 patches were generated. The resulting dataset 
consisted of multiple .zip archives consisting of the patch and a matching mask 
(Fig. 3B). The mask represented pathologistsʼ annotations meaning that each 
pixel had an integer value corresponding to one of the following classes: 0 – 
gaps, 1 – glands, 2 – nerves, 3 – stroma, 4 – fat. The majority of patches had an 
admix of at least two components; images were grouped by class by deter-
mining the dominating element for each mask: 
0. gaps, 3865 
1. glands, 7600 
2. nerves, 20689 
3. stroma, 48626 
4. fat, 33409 
 
The training process requires rather powerful machines; it can be done locally, 
but there are openly available and convenient cloud solutions. The patches were 


















































































































As can be seen from the above mentioned, the number of patches between 
groups varied significantly, which is evident since almost all patches had a 
stromal component. The different proportion of patches impacts the predictive 
value of the model. Because of the problem with class imbalance, the training 
dataset had to be balanced with both oversampling and undersampling techni-
ques. 1000 samples were taken out from each group to build the intermediary 
validation dataset; remaining images were used for training, resulting in the fol-
lowing dataset: 
0. gaps, 19689 (random oversampling) 
1. glands, 19689 (random oversampling) 
2. nerves, 19689 (base count, the main point of interest) 
3. stroma, 19689 (random undersampling) 
4. fat, 19689 (random undersampling) 
 
Oversampling duplicates samples and can result in overfitting, making the 
modelʼs predictions less accurate in new data. Undersampling removes samples 
from the dataset, which can result in the loss of important information required 
for training. In our case, the information in stroma and fat samples was repeti-
tive and could be undersampled without valuable information loss. Samples 
with gaps are nearly identical and can be heavily oversampled. There was a risk 
of overfitting gland samples, but it did not turn out to be a problem. 
The augmentation of the histological image is currently a topic of interest for 
data scientists in DP since usual techniques such as width shifts, height shifts, 
and zoom changes, which make images blurry on the outer sides, result in loss 
of valuable information in medical images. In the current manuscript, only 
vertical and horizontal flips were applied. 
A Fully Convolutional Network Model model with the architecture that 
proved its efficiency in multiple biomedical studies was used for the multiclass 
semantic segmentation task (Falk et al., 2019). The architecture has a symmetric 
U-shape with the contraction path (encoder) on the left-hand side, where regular 
convolutions and max-pooling layers are applied. On the right-hand side is the 
expansion path (decoder), where we apply transposed convolutions with regular 
convolutions. The size of the input image is 256×256×3. The model has 5 
classes with a Softmax activation layer, resulting in the 256×256×5 output size. 
The model was trained for 13.2 hours in Google Colaboratory using the 
Tesla K80 GPU. The training was performed with a validation set using the 
sparse_categorical_crossentropy loss function since the mask pixel values are 
integer class values. The training process consisted of 30 epochs (1586s per 
epoch) and resulted in a validation loss of 0.0742. 
Moreover, we attempted to train a model without a validation set. The 
trained model had a loss value of 0.0497. Although the loss value was lower, 




For validation, 50 of 1×1 millimeter ROI from 10 biopsy samples and 25 RP 
were analyzed. The ROI had at least two components and diverse structural 
complexity. The pathologists were asked to measure the area of the structural 
elements inside the ROI on the H&E stained sample; afterward, the trained 
model was applied to the ROI. The following parameters were calculated for 
each of five components per ROI: 
1) Real composition of the ROI, as measured by the pathologist (R), mm2 
2) ML measured composition (M), mm2 
3) False-positive area (FP), mm2 
4) False-negative area (FN), mm2 
5) Error, FP+FN, mm2 
6) The true-positive area by ML (TP), mm2 
7) Precision, defined as the number of correct positive predicts = TP/(TP+FP) 
8) Recall defined the number of predictions made out of all positive examples 
in the testing dataset = TP/(TP+FN). 
9) F1, a harmonic mean of precision and recall = 2 × Precision × Recall/ 
(Precision+Recall). 
 
Precision, recall, and F1 are the most important results in the context of model 
applicability. 
Such an approach has become a standard for the validation of machine 
learning algorithms (Enomoto et al., 2006; Mäkelä et al., 2021) 
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6.8 Quantification of MT, FANCM, and Ki67 
6.8.1 MT and FANCM in RP 
After the main feature of Pathadin was ready for use, it was tested for practical 
application. 
As the review of literature displayed controversies addressing stromal changes 
around PCa, the quantification of microenvironmental changes to establish 
general trends around carcinomatous nests was first performed on RP: there is 
more material in RP, and cancerous areas and the differentiation are clearly 
distinguishable; thus, the impact of the glandular component to the surrounding 
microenvironment could be evaluated precisely. 
For FANCM, RP samples of 60 patients were analyzed. The ISUP grades 
were as follows:  
• G1= 13; G2= 9; G3= 11; G4= 15, and G5= 12. 
• MT: G1= 15, G2= 15, G3= 15, G4= 15, and G5= 12. 
• Ki67: G1= 15, G2= 15, G3= 15, G4= 15, and G5= 12. 
 
In addition to radical prostatectomy, 11 autopsy samples were retrieved for 
control (CTRL) from patients with no previously known or discovered autopsy 
prostatic diseases and stained with all three markers.  
All the slides were divided into 1000x1000 µm (1 mm2) regions of interest 
(ROI). From each cancerous slide, five ROIs from the normal non-cancerous 
(NCT) and five from the cancerous tissue were randomly selected for the 
analysis. In the case of the ROI consisting mainly of confluent epithelial nests 
(as in G4–5) and almost devoid of detectable stroma, the selection was 
manually drifted by one grid frame to include the closest stromal area adjacent 
to the cancer nest. 655 FANCM, 775 MT, and Ki67 1 mm2 ROI were analyzed 
to evaluate the mean change per patient. 
The covered area of 10 mm2 per slide is approximately equal to the total sur-
face of a single biopsy, consisting of both cancerous and cancer-free compo-
nents. 
As the ROI was selected and segmented into components by the trained ML 
algorithm, for FANCM and MT, the stromal staining index (SSI), defined as the 
percentage of the staining positive stroma over the total stroma in the ROI, was 
calculated. The HSV (hue, saturation, value) color model, an alternative to RGB 
with more precise alignment with the way human vision perceives color-making 
attributes, was used: 
• For MT, the stromal staining index (SSI), a percentage of the collagen amount 
(green staining) of stroma over the total, was automatically calculated using 
the following settings H (50–135), S (0–255), and V (0–255) for green/ 
blueish color. 
• For FANCM, to quantify SSI of brownish DAB, settings were as follows: H 
(0–35), S (30–255), and V (0–220). 
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The selection of settings and analyses were performed under the visual control 
of two pathologists. 
For Ki67, the validation method described in part 4.6.4 was applied. For 
DAB positive cell detection in the separated glands, the integrated module by 
HistomicsTK ver. 1.1.0 was used. 
The settings for HSV and Histomics were defined empirically by two patho-
logists. All the analysis was performed under the visual control of pathologists. 
The main steps of the workflow are demonstrated in Figure 4. 
 
 
Figure 4.  The workflow of image ana-
lysis. 
A.  FANCM, MT, and Ki67 stained 
glasses were prepared. 
B.  The set of glasses for training (H& 
E) and analysis (H&E, Ki67, MT, 
FACM) were scanned at 20x mag-
nification with a resolution of  
0,24 μm/px. 
C.  The training set was annotated by 
pathologists into stroma and glands 
and sliced into tiles. 
D.  The U-net model, in combination 
with Googleʼs Colab, was trained 
for gland and stroma segmentation. 
E.  The trained model was applied to 
highlight glands and stroma on the 
1 mm2 ROI on the set of analytical 
H&E, facilitating the selection of 
these components by pathologists. 
F.  The selection of glands or stroma 
on the ROI was placed to the cor-
responding area on MT, FANCM, 
and Ki67 stained glasses. The 
amount of collagen in ROI was 
evaluated using the HSV color 
threshold. The expression of Ki67 
defined as DAB positive nuclei to 
all glandular nuclei per 1 mm2 (%) 
was quantified using HisomicsTK. 
(abbreviations: MT-Massonˇs Trichro-




6.8.2 MT and FANCM in the biopsy 
First of all, grade-associated changes have to be evaluated in RP samples to des-
cribe general trends in staining behavior. The next step is to determine if these 
changes can be extrapolated and have any value in the limited volume of biopsy 
samples. As the quantification of Ki67 in glands would not be different in 
biopsies, only MT and FACM were used in further analysis. 
Unlike RP, the whole biopsy was analyzed. The HSV parameters were left 
the same. It is essential to articulate that analyzed samples were only from the 
peripheral part, excluding anterior fibromuscular stroma. Thus, the zone-depen-




Pairwise Wilcoxon Rank Sum test was used to compare SSI of FANCM, MT, 
and Ki67 among different Gleason grade groups, and controls in RP two-one-
sided t-tests (TOST) was used to demonstrate the equivalence between cada-
veric samples and non-cancerous tissue in RP A Wilcoxon signed-rank test was 
used in biopsies to establish if there is a statistically significant difference 
between the test and control groups. 
A p-value of less than 0.05 was considered statistically significant after the 
Bonferroni correction. Spearmanʼs ρ was used to show the dependence of 
FANCM of the age group. The charts were made using Excel, statistics were 





7.1 The trained U-net model can quickly and reliably 
segment histological slides into components 
Prior to the analysis of PCa associated changes, the computer was trained to dis-
tinguish five components of the prostate: glands, stroma, nerves, fat, and gaps. 
Two pathologists evaluated ML resultsʼ quality; examples of H&E ROI and 





Figure 5. Sample of ML performed tissue segmentation. 
A. Validation of ROI sized 1x1 mm2, H&E staining.  
B. ML analysis results. Stroma is highlighted green, nerves bluish-green, glands dark-
blue, gaps violet, and fat yellow. The color scheme can be easily modified. 
(abbreviations: ML- Machine Learning, ROI- region of interest) 
 
 
The average time of the ROI analysis was 3.4 seconds. Cumulative model effi-
ciency, covering all the five components: error was 4.598 mm2, precision was 
95.3%, recall 95.5%, F1 95.4%, 
Stroma was present in all the 50 ROI, with 22.404 mm2 annotated by patho-
logists. Efficiency of ML: error 1.845 mm2, precision 95.7%, recall 96.1%, F1 
95.9%. It is important to emphasize that the error, both false-positive and  
-negative, was mainly caused by the misinterpretation of nerves. 
Neural tissue, including ganglia, was present in 38 ROI, with 4.391 mm2 
annotated. Efficiency: error 1.382 mm2, precision 80.5%, recall 90.5%, F1 
85.2%. Nerves posed a major challenge for ML, especially in the desmoplastic 
stroma, being frequently false-positive. In a single ROI, pale-colored sheets and 
scattered carcinoma cells were also wrongly interpreted as nerves, mimicking 
ganglion cells. 
The glandular component was present in 31 ROI, covering an area of  
10.950 mm2. Efficiency: error 0.726 mm2, precision 98.9%, recall 94.5% and F1 
39 
96.6%. No consistent pattern in mistakes was found, with the main cross-re-
action with neural and stromal tissue. 
Fat presented in 15 ROI with a total area of 4.460 mm2. Efficiency: error 
0.276 mm2, precision 98%, recall 97.2% and F1 97.6%. As expected, the pri-
mary mismatch was due to the fragmentation and deformation of adipocytes, 
interpreted as empty areas or secretion components, and artificial masses inside 
the gaps interpreted as fat. 
Empty areas (gaps), represented mainly as lumens of glands and blood 
vessels, were annotated in 44 ROIs, covering the area of 7.95 mm2. Efficiency: 
error 0.368 mm2, precision 98%, recall 97.2 and F1 97.6%. 
The summary of calculated parameters per component is provided in Table 3. 
 
 
Table 3. The result of prostate tissue segmentation. 
 
  Stroma Nerves Glands Fat Empty 
Pathologist, mm2 22.404 4.391 10.950 4.460 7.795 
Machine, mm2 22.483 4.949 10.464 4.463 7.640 
False-neg. mm2 0.878 0.417 0.606 0.137 0.213 
False-pos. mm2 0.967 0.965 0.120 0.140 0.155 
Error, mm2 1.845 1.382 0.726 0.276 0.368 
True pos., mm2 21.525 3.984 10.344 4.323 7.485 
Precision 0.957 0.805 0.989 0.969 0.980 
Recall 0.961 0.905 0.945 0.969 0.972 
F1 0.959 0.852 0.966 0.969 0.976 
 
 
7.2 PCa associated changes in radical prostatectomy 
As the ML model was created to help the independent analysis of prostatic 
components, the next step was to quantify the PCa associated changes in RP 
and biopsies. Only biopsies have limited volume; thus, general tendencies in 
changes had to be first evaluated in RP to further extrapolate these in biopsies. 
 
7.2.1 Massonʼs trichrome staining demonstrates the grade-
dependent gradual increase of relative collagen amount in PCa 
The Trichrome III Green Staining Kit stains collagen green, muscle and erythro-
cytes red, and cell nuclei blue-black. In CTRL and NCT, stroma was predo-
minately red because of a high composition of smooth muscle found in thick 
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extensive bands. The mean SSI of CTRL and NCT was 28 ± 8.1 (2SD) and  
26.9 ± 7.8, respectively (Table 4, Fig. 6). The TOST equivalence test demon-
strated the equivalence of SSI and CTRL, and NCT (p= 1). Figure 7 
demonstrates the stepwise increase of reactive stroma in PCa until it becomes 
almost fully green with some small areas of entrapped bundles of smooth 
muscle in G5. The increase in SSI was statistically significant between CTRL 
and G1 carcinoma (mean SSI= 28% vs. 40.5 %; p< 0.001). A statistically 
significant elevation in the collagen level was also detected between G1 (40.5 %) 
and NCT (26.9 %), p< 0.001, and G3 (50.3%) vs. G4 (83%), p< 0.001. The 
differences remained statistically insignificant between G1 (40.5 %) vs. G2 
(44.2%), p= 1; G2 (44.2 %) vs. G3 (50.3 %), p=0.06; G4 (83.0%) vs. G5 
(83.6%), p= 1. 
 
Table 4. SSI of collagen depending on ISUP grade. 
 
  CTRL NCT G1 G2 G3 G4 G5 
  (n=11) (n=72) (n=15) (n= 15) (n= 15) (n= 15) (n= 12) 
Mean % 28 26.9 40.5 44.2 50.3 83 83.6 
± 2SD 8.1 7.8 12.4 9.9 8.2 7 8.5 
Median % 28.8 26.6 42.2 44 49.8 83.2 84.2 
Min. value 22.4 18.8 21.8 37.2 43.6 78.4 75.4 
Max. value 36.4 35.2 46.8 52.2 58.2 89.4 91.6 
 
 
Figure 6. ISUP grade dependant stepwise increase of collagen SSI (green in MT). 
(abbreviations: CTRL- control group (autopsy), G- grade group, NCT- non-cancerous 






















































































































































































7.2.2 Stroma-specific strong expression of FANCM in autopsy 
prostate and non-cancerous radical prostatectomy areas 
This work is the first one to evaluate FANCM staining in the prostate tissue 
systematically. The FANCM immunohistochemical expression was analyzed in 
11 cadaveric prostates for controls and non-cancerous tissues from 60 radical 
prostatectomy samples with carcinoma diagnosis. Strong diffuse cytoplasmic 
expression of the FANCM protein was detected in smooth muscle cells in 
autopsy CTRL and NCT prostate tissues; a weak FANCM positivity was also 
observed in glandular compartments of either normal or cancerous epithelial 
nests, but only when incubating in a 20- fold increased antibody concentration. 
Furthermore, FANCM positive staining was detectable along the walls of blood 
vessels and, to a smaller extent, in nerve fibers. 
TOST equivalence test demonstrated that FANCM expression between two 
non-cancerous control sample sets of CTRL and NCT were equivalent 
(p<0.001), the mean values of SSI being 39.1% and 41%, respectively (Table 5, 
Fig. 8). The patientsʼ age at sampling (47–89 yrs.) did not show a strong as-
sociation in correlation to the intensity of FANCM expression (Spearmanʼs ρ= 
0.136; p= 0.01). 
 
 
7.2.3 FANCM staining demonstrates a grade-dependent gradual 
decrease in staining intensity PCa 
In the controls, the intensely diffused FANCM positive stroma extended as 
close as to the basement membrane of normal prostatic glands; however, the 
cancerous glandular complexes appeared to be surrounded by a notably less 
intensely FANCM stained stromal rim already at the lowest G1 grade. The step-
wise decline of FANCM staining intensity was apparent in each next grade until 
becoming barely visible in the highest G5. In G5 carcinoma, only the walls of 
blood vessels remained FANCM positive (Fig. 9). 
SSI per patient demonstrated a statistically significant decline in the mean 
SSI (%) in G1 (27.7%) vs. CTRL (39.1%) and NCT (41%), p= 0.001 and 
p<0,001, respectively. A statistically significant drop in the FANCM expression 
level was also detected between G2 (24.7%) vs. G3 (17.6%), p=0.005. Diffe-
rences remained statistically insignificant for declines G1 (27.7%) vs. G2 
(24.7%), p= 0.3; G3 (17.6%) vs. G4 (14.2%), p= 0.06; and G4 (14.2%) vs. G5 
(12.4%), p= 1. 
The grade-dependent decline of staining intensity in the cancerous specimen 
was evident both per surface area and per individual stromal cells when the 
prostatectomy data were analyzed per each cancer patient with a spectrum of 
identified grade groups. 
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Table 5. SSI of FANCM depending on ISUP grade. 
 
  CTRL NCT G1 G2 G3 G4 G5 
  (n=11) (n=60) (n=13) (n= 9) (n= 11) (n= 15) (n= 12) 
Mean % 39.1 41 27.7 24.7 17.6 14.2 12.4 
± 2SD 10.8 9 6.1 3.9 5 5.3 3.9 
Median % 39 41.8 28.2 25 17.9 13.5 11.8 
Min. value 32.4 32.1 23.9 22.1 13 11 9.4 






Figure 8. ISUP grade depending stepwise decrease of FANCM SSI. 
(abbreviations: CTRL- control group (autopsy), G- grade group, NCT- non-cancerous 




































































































































































7.2.4 Ki 67 staining demonstrates ISUP grade-dependent gradual 
increase in PCa 
Ki67 quantification (positive nuclei/all epithelial nuclei per 1 mm2, %) was per-
formed under the control of two pathologists: the percentage of DAB positive 
and negative cells was calculated using an open-source module by Histomics 
for cell counting. The module was integrated into Pathadin and counted cells 
according to empirically defined staining intensity and size (radius, area, the 
distance between cells). Overall, 775 1 mm2 ROI were analyzed. 
Averagely, the analysis of a single ROI was performed in 2 seconds (1–3 
sec.). Based on all counted DAB positive and negative cells, the precision was 
86.5%, recall 82.1%, and F1 84.2%. The algorithm failed in some cases of 
overlapping cells: this was especially prominent in high-grade carcinomas with 
many Ki67 positive nuclei of different staining intensity in G4 and G5 samples. 
29% (39 of 135) of analyzed ROI taken from these areas had more than 25% of 
wrongly identified cells. In CTRL and G1-G3 samples with only single Ki67 
positive cells, mistakes remained insignificant, with a failure rate of 4% (27 of 
640) in the remaining ROI. 
Ki67 expression, evaluated by computer and corrected by human vision, was 
almost undetectable in CTRL and NCT, with a mean value of 1.1% (±0.7) and  
1 (±0.7%) per mm2 , respectively. The TOST equivalence test showed the equi-
valence of CTRL and NCT (p=1). The stepwise increase of Ki67 was seen in 
cancerous tissue: a statistically significant elevation in Ki67 was detected 
between CTRL (1.1%) and G1 (8.0%), p<0.001; NCT (1.0%) and G1 (8%), 
p<0.001; between G2 (8.9%) and G3 (14.5%) (p<0.001); G3 (14.5%) vs. G4 
(23.5%) (p<0.001). Differences remained statistically insignificant between G1 





Table 6. Ki67 % per 1 mm2 depending on ISUP grade. 
 
 CTRL NCT G1 G2 G3 G4 G5 
 (n=11) (n=72) (n=15) (n= 15) (n= 15) (n= 15) (n= 12) 
Mean % 1.1 1 8 8.9 14.5 23.5 27.8 
± 2SD 0.7 0.7 3.3 3.1 6.5 10.6 16.2 
Median % 1.2 1 7.8 9 13.8 22.4 27.1 
Min. value 0.4 0.2 5.6 6.4 8.6 17.6 16.4 





Figure 10. Stepwise increase in Ki67 depending on ISUP grade. 
(abbreviations: CTRL- control group (autopsy), G- grade group, NCT- non-cancerous 














































































































7.3 PCa associated changes in the biopsy 
Following the analysis in RP, the MT and FACNM stainings combined with 
validated DP algorithms were applied to a limited volume of the biopsy. 
 
7.3.1 G1 is most frequently upgraded and rationale  
for analysis in a biopsy 
Taking into account the following facts:  
1. There are markers to distinguish benign and cancerous changes (Alpha-
methylacyl-CoA racemase, p63, and High Molecular Weight Cytokeratin 
cocktail). 
2. G1 is the most frequently diagnosed differentiation grade (Eggener et al., 
2015) and most frequently updated, as confirmed in our cohort – of 128 up-
graded cases, 82 were G1: 59 changed to G2, 16 to G3, and 7 to G4. 
3. False-positive G1 in biopsy may lead to a less radical treatment decision. 
4. It was demonstrated on RP that stromal changes alone could not distinguish 
adjacent ISUP grades. 
It was concluded that the only practical use of stromal changes in the current 
clinical paradigm would be in cancer-free samples to predict the existence of 
cancer at all and in G1 biopsies to predict less differentiated cancer nearby. 
To test the hypothesis, the following groups of biopsies were formed:  
(1) The control group (CG)- biopsies with G1 carcinoma, where no upgrade 
happened. 
(2) The test group (TG), covering all patients with upgraded G1 biopsies. Test 
groups included samples with carcinoma (TGC) and samples without cancer 
(TGW) retrieved from the same patient. 
As the prostate histology depends on the zone, the samples from the peripheral 
part were analyzed, excluding anterior fibromuscular stroma. In TGC, biopsies 
from the site of the highest ISUP grade in the RP were retrieved. In the case of 
several positive samples, the biopsy with the highest percentage of the area of 
the cancerous component was included. From the CG, biopsies with the highest 
percentage of the cancerous area were retrieved. 
All the upgraded 82 G1 (TG) were stained with FANCM and MT and com-
pared with 50 samples without the upgrade (CG). Table 7 summarizes biopsy 
and RP cancer data along with available PSA values of study patients, including 
the extent of distribution in the prostate. Although some tumors were also 
present in the transitory and central zones, only biopsies from the peripheral 




Table 7. Information on included G1 patients and samples 
 
 TG CT 
Age at biopsy 63.4 ± 6.5 62.5 ± 5.9 
Total PSA (ng/ml) 6.41 ± 1.92  5.9 ± 1.6 
Biopsy:     
Number of cores 9.6 (8–12) 9.4 (8–12) 
Positive cores 2.3 (1–7) 2.6 (1–8) 
Area of the core (mm2) 6.1 ± 1.7 6 ± 1.8 
% of microenvironment 66.9 ± 14.2 70 ± 14.1 
% of cancerous glands 15 ± 3.3 14.8 ± 2.9 
Tumor presence in RP:     
Central 2 0 
Transitory 11 7 
Peripheral 82 50 
Anterior fibromuscular 5 1 





7.3.2 Massonʼs trichrome displays a statistically significant 
change between cancerous and cancer-free samples but not 
between upgraded and non-upgraded 
Biopsy samples with an upgrade in RP were compared with samples without the 
upgrade and samples without cancer. Using MT stain, the change in the quantity 
of collagen (bluish color) was analyzed with the SSI and expected to be higher 
in carcinomas. The mean SSI in non-upgraded (control group, CG) biopsies was 
41% (20–78); 44% (23–89) in samples from upgraded cancerous group (TGC) 
and 37 % (15–57) in samples without cancer (TGW) (Fig. 12). 
No statistically significant difference was found between non-upgraded and 
upgraded groups (p=0.84). SSI of 31 samples in the TGC group was higher than 
95 CI of the CG (38–44 %), with 4 of 7 samples from the region of G4 carci-
noma being among these samples. 
The difference between TGC and TGW appeared to be statistically signi-





Figure 12. Massonʼs trichrome staining in different biopsy samples. 
Compared to samples without cancer (TGW), in cancerous samples (CG and TGC), the 
number of collagen fibers is higher (bluish), the muscles are fragmented and thinner. In 
some cancerous samples taken from the area where the ISUP upgrade happened, there is 
only a minimal residual muscular component. On the right, an overview of SSI distri-
bution in different samples is presented; a significant overlap between the groups is 
seen. The “X” on the barplot indicates the mean value of SSI. 
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7.3.3 FANCM displays a statistically significant change between 
cancerous and cancer-free samples but not between upgraded 
and non-upgraded 
Biopsy samples with an upgrade in RP were compared with samples without 
upgrade and samples without cancer. With FANCM, the quantity of DAB posi-
tive stromal elements was evaluated, with the SSI expected to be lower in 
carcinomas. The mean SSI in the non-upgraded (CG) was 36% (13–59); 34% 
(9–58) in samples from the upgraded cancerous group (TGC), and 44% (22–69) 
in the group without cancer (TGW) (Fig. 13). 
No statistically significant difference between the non-upgraded (CG) and 
the upgraded (TGC) specimen was found (p=0.5). SSI of 37 samples in the 
TGC group was higher than 95 CI of the CG (33–40%), with 5 of 7 samples 
from the region of G4 carcinoma being among these samples. 
The difference between TGC and TGW appeared to be statistically signi-




Figure 13. FANCM staining in different biopsy samples. 
Compared to samples without cancer (TGW), in cancerous samples (CG and TGC), the 
amount of DAB is significantly lower. In some cancerous samples taken from the area 
where the ISUP upgrade happened, there is almost only hematoxylin. On the right, an 
overview of SSI distribution in different samples is presented; a significant overlap 




8.1 FANCM and MT in radical prostatectomy samples 
FANCM immunohistochemical expression in stroma has been previously 
described in a few normal prostate samples, but this larger cohort analysis was 
the first systematic comparison of FANCM immunohistochemical expression in 
normal and cancerous prostate samples. The analysis was performed with a 
simultaneous evaluation of stromogenic changes in MT, straining muscles, and 
collagen, to display a simultaneous decrease in smooth muscle cells and in-
crease in collagen composition proportionally to the ISUP grade. The current 
study confirmed FANCM expression to be highly stroma-specific in the normal 
prostate and showed a grade-dependent gradual decline in prostate carcinoma. 
Per patient, the difference remained statistically insignificant between adjacent 
ISUP grade groups, except G2 vs. G3 and G1 vs. controls. 
This morphological study demonstrated there was no difference in FANCM 
expression between unaltered stromal areas from cancer patients and the stroma 
of the prostate from cancer-free controls, thus indicating the absence of under-
lying baseline alterations in FANCM protein expression, which could poten-
tially affect susceptibility to PCa in our entire cohort. 
The studies in animal models and human PCa report the phenotype change 
in reactive tumor stroma with loss of myoepithelial cells and an increase in the 
proportion of CAFs (Gravina et al., 2013; Yang et al., 2017). It suggests that 
FANCM depletion is a secondary change, corresponding to the formation of the 
reactive tumor stroma.  
Prior to the current paper, there have been no reports on the role of homo-
logous recombination DNA repair pathway protein expression in the cancer 
stroma. Various other expression pattern changes of these proteins have been 
reported in the epithelial compartment of PCa: BRCA1 was increasingly ex-
pressed in cancer cell nuclei in higher grade PCa, heralding worse clinical out-
comes (Fiorentino et al., 2010; Schayek et al., 2009). BRCA2 has revealed a 
much more sophisticated response as membranous staining declined, but cyto-
plasmic expression increased with higher grade, and, notably, lack of C-ter-
minal expression in the cytoplasm was associated with a reduced risk of rapidly 
fatal prostate cancer (Thorgeirsson et al., 2016). Results of FANCM expression 
in the prostate draw attention to the potential role of the homologous recombi-
nation DNA repair pathway in cancer-associated stromal changes and their 
further research. Of notice, if used in ultra automated stainer, the FANCM anti-
body from Novus Biologicals appeared highly cost-effective, gaining optimal 
stromal staining at 1:2000 dilution. 
Even though Massonʼs trichrome being a widely available staining, we 
didnʼt find a simple method of precise quantifying collagen. In this manuscript, 
an HSV color model was applied, providing the results in seconds. An 
alternative solution would be K- means color clustering, included in Pathadin: 
an objective yet straightforward and difficult to manipulate method, less precise 
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in some cases. As with FANCM, Massonʼs trichrome staining demonstrated a 
statistically significant gradual increase in the collagen amount in PCa, 
depending on ISUP grade, but not between the adjacent groups – there was 
considerable overlap in 95 Cl. On the other side, there was only a minor overlap 
between low and high-grade carcinomas. 
In conclusion, both markers displayed insufficiency in distinguishing adja-
cent grade groups or detecting stromogenic reactions in non-affected parts of 
the prostate. On the other hand, it is essential to emphasize that there is evidence 
that mortality in the G2 group is only slightly higher than G1 (Rider et al., 
2013), while men with high-risk localized PCa or more advanced disease have 
substantially higher mortality compared with G1 and G2; there is some over-
lapping in SSI between adjacent grade groups, but there is only minor over-
lapping between low- and high-risk carcinomas defying clinical prognosis. 
 
 
8.2 FANCM and MP in biopsy: diagnostic significance and 
practical application 
The essential part of the work was to evaluate whether microenvironmental 
changes found in RP are applicable to biopsies. For this purpose, biopsy and RP 
samples of 385 patients were reevaluated. 
Results of the biopsy analysis showed that G1 carcinomas are most fre-
quently diagnosed and further upgraded in RP. In G1 carcinomas, stromal 
staining indices appeared to overlap with ones from RP with upgraded PCa. 
However, the difference between cancerous and non-cancerous samples bore 
statistical significance.  
The amount of stromogenic reaction is traditionally graded qualitatively: 
minor, moderate, and extensive, for example, as there is no simple way for a 
quantitative analysis of stroma using only human vision. Such gradation is easy 
to use; however, it loses its precision and is not applicable in new markers and 
experimental works. Digital pathology analysis performed in this work allows 
performing stromal staining quantification of the entire biopsy material rapidly. 
As biopsies cover only a tiny part of the prostate and provide limited infor-
mation, which can be significantly impacted by preanalytical procedures, stro-
mal changes could potentially predict the presence of higher grade carcinomas. 
Two markers, MT and FANCM, which in previous publications demonstrated 
the grade-dependent change of expression in RP, were analyzed in biopsies to 
test two hypotheses. 
First, stromal statistically significant composition differences could be 
revealed between cancerous and non-cancerous areas from the same anatomical 
locations both by FANCM and MT stain.  
The moderate sample size and inclusion of G1 in this study represented a 
realistic clinical setting, and as it showed overlap in SSI between the G groups, 
the routine use as a discriminative marker canʼt be advised. Also, it should be 
kept in mind that in the case of elderly patients, stromal changes can be caused 
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by other conditions, such as, for example, stromal hyperplasia or inflammation, 
which in terms of the limited size of the sample could be challenging to distinguish.  
Secondly, a difference in the stromal compound between samples with and 
without ISUP upgrade in RP was analyzed, as, presumably, stromogenesis is 
correlated with cancer differentiation. We found no statistically significant 
difference between these groups. To some extent, this can also be caused by a 
consciously original routine cohort with the predominant upgrade from G1 to 
G2. The expectation to distinguish adjacent groups with stromogenetic changes 
in biopsies is somewhat optimistic, especially, taking into count that the stromo-
genic changes are apparent only on a limited distance. Promisingly, some SSI 
values were outside the 95% interval of the control group, meaning that there 
can be found a cutoff value for SSI in G1 carcinomas, which could help predict 
changes to a higher grade in the area of the biopsy. 
In conclusion, despite somewhat similar results in MT and FANCM stai-
nings, it could be seen that the overlap in SSI expression in FANCM was slight-
ly less. Taking into account the availability of different stromal markers, which 
could potentially show higher specificity and sensitivity, and modern solutions 
in image analysis, it can be encouraged to study the composition of stroma with 
new emerging stains. 
 
 
8.3 Ki67 in radical prostatectomy samples 
The quantification of nuclear IHC is no longer an experiment, rapidly becoming 
a routine solution, provided by commercial (e.g., CellQuant by 3DHistech) and 
open-source tools, such as Histomics. Although Ki67 is not frequently used in 
PCa, it is one of the most popular stains, which requires precise and time-con-
suming calculations; for this reason, it was decided to be included in the current 
work. The module showed its effectivity, calculating the % of Ki67 staining in 
PCa, only struggling with overlapping cells of G4 and G5 carcinomas. It should 
be articulated that better precision could be achieved with algorithms oriented 
for a single task, explicitly (Acs et al., 2018; Saha et al., 2017); Histomics was 
selected for its simplicity in use and universality. 
Under the visual control of pathologists, results demonstrated the correlation 
between Ki67 expression and Gleason score in numbers similar to the large 
Ki67 studies (Richardsen et al., 2017; Tretiakova et al., 2016b). 
 
 
8.4 Application of digital pathology and machine learning 
in the prostate histology 
The critical part of PhD studies was to create an easily reproducible multiclass 
model for PCa compartments analysis to see if advanced digital pathology 
solutions can already be helpful in daily routine. For this purpose, the segmen-
tation of prostatic tissue into five universal components, meaning it can be 
adapted to samples of many different types, was created. 
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Although the model was quick and displayed a high predictivity rate as well 
as was seemingly simple, it posed some challenges we struggled to overcome. 
Distinguishing fat tissue and empty areas is essential in the theoretical para-
digm of fully automated analysis in order to avoid a false-positive pT3a stage. 
In single ROIs, gaps included processing caused artifacts, such as eosinophilic 
stripes or thin tissue fragments. The algorithm counted them as adipocytes. 
Fortunately, the problematic areas were small, and the background remained 
genuinely true. 
Significantly more challenging was to distinguish between stroma and nerves. 
Areas of fibrous proliferate, such as stromal hyperplasia or desmoid reaction, 
especially in older, manually-stained slides specifically found from the archives, 
were occasionally interpreted as nerves. These slides may have grayish areas with 
lesser eosin and, especially if stretched in a biopsy, can indeed mimic nerves even 
for an experienced eye; at this point, only IHC can be decisive. Neither the dataset 
enlargement nor manipulations with magnifications or patch size impacted the 
outcome; the model fluctuated between false-negativity and false-positivity in 
nerve detection. For such cases, IHC cannot be replaced. 
In some ROIs, the ML segmentation mask appears to be prominently angular 
and square. This effect is due to the final image being composed of smaller 
256x256 px patches, generated using a step size that is equal to the patch size, 
making the patches non-overlapping. For ML, a tissue element, such as a nerve, 
extending between several patches and recognized as a single structure by the 
pathologist, is composed of independent images. The residual part of an element, 
extending across the border of an adjacent patch, loses prominent features 
required for the model to assign it to the same class as the main body, resulting in 
the sharp demarcation between adjacent mask elements. This can be easily fixed 
by changing the step of ML and thus creating an overlay of the patches. It will 
make a better visual outcome but results in a slightly increased analysis time.  
On the other hand, as concluded from experiment results, ML can be reliably 
used to quantify secondary features before the sample gets to the pathologist, 
thus simplifying their work. These features are not as sensitive and pathologist-
dependant as Gleasonʼs grade but still essential and time-consuming to report. 
The model can be combined with the cellular analysis, as, for example, the IHC 
quantification or detection of inflammatory cells; these algorithms are available 
in many open-source solutions, including Pathadin. 
Currently, Pathadin includes only a few features but is rapidly evolving, 
aiming to make use of computer-assisted analysis as convenient as possible. It 
demonstrates that there is no need for significant resources to experience the 
advantages of modern computer-assisted analysis. WSI analysis is a relatively 
new world, full of new ideas. A pathologist should be encouraged to test 
experimental open-source algorithms, both by individual developers and giants, 
such as Google, as well as give feedback and advice on the provided solutions. 





The main task of the work was to objectively analyze the amount and diagnostic 
significance of carcinoma-associated microenvironmental changes around diffe-
rent Gleason grades and the practical use of such changes, especially in bio-
psies. 
Given that the microscope has limitations to perform the precise evaluation 
of histological changes, a tool based on modern digital pathology solutions was 
developed and tested. 
The results in logical chronology are as follows: 
1. The created open-source tool for WSI-oriented analysis, Pathadin, performed 
successfully in: 
1.1. Quick, objective, and reproducible research of staining on histological 
samples using color analysis algorithms (HSV thresholding). 
1.2. Quantification of DAB positive nuclei in Ki67 stained samples. The 
analysis performed under the visual control of pathologists showed that 
despite Gleason-dependent differences, the overlap between the adja-
cent grade groups limits the clinical application. 
1.3. Preparation of image datasets for the training of the machine learning 
algorithms. 
1.4. Testing, visualization, and validation of trained machine learning model. 
2. A U-net model distinguishing glands, stroma, nerves, fat, and gaps was 
created and validated for further independent analysis of the experimental 
material. 
3. The combination of the trained model and color analysis algorithms used in 
the Pathadin environment was applied to evaluate the microenvironmental 
changes around different cancer grade groups: firstly, in radical prosta-
tectomy samples, afterward – in biopsies to understand the practical value 
for diagnostics. 
3.1. In radical prostatectomy samples: 
3.1.1. FANCM, a novel marker, was for the first time systematically 
described in prostate adenocarcinoma. It showed stromal speci-
ficity and grade-dependent decline in the carcinoma micro-
environment and indicated the potential role of the homologous 
recombinant pathway in cancer stroma. FANCM protein baseline 
expression in normal prostate stroma did not affect the suscepti-
bility to adenocarcinoma. 
3.1.2. Massonʼs trichrome (the analyzed staining of collagen) also 
demonstrated a grade-dependent change in expression and a 
difference between cancerous and non-cancerous areas. 
3.1.3. Both markers had a significant overlap in expression between the 
adjacent grade groups. The overlap was minimal between low 
(G1)- and high-grade (G4 and G5) carcinomas and between 
cancerous versus cancer-free areas. 
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3.2. In biopsies: 
3.2.1. It was confirmed that G1 prostate carcinoma is diagnosed and 
upgraded most frequently. 
3.2.2. Stromal composition quantification based on FANCM and Mas-
sonʼs trichrome stainings showed a statistically significant diffe-
rence between non-cancerous and cancerous areas with G1 diffe-
rentiation. 
3.2.3. Despite the confirmed statistical significance, considerable over-
lap in expression between G1 and non-cancerous tissue is a limi-
tation for FANCM and Masson`s trichrome differential diagnos-
tic use in biopsies a thus in clinical practice. 
 
The created methodology is universal. Using the guidelines and samples pro-
vided in the repository (https://gitlab.com/Digipathology/Pathadin; https:// 
github.com/ geodza/Pathadin) can serve as a manual for anyone willing to 
understand the basics of computer-assisted pathohistological diagnostics as well 
as assist in the creation of oneʼs own model or quantification of microen-
vironmental changes in different tissues. 
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10. IMPLICATIONS FOR PRACTICE 
1. FANCM, a homologous recombinant pathway protein, appears to be a novel, 
highly stroma-specific immunohistochemical marker in the prostate, showing 
the grade-dependent decline in the carcinoma microenvironment. This out-
lines the potential role of homologous recombinant pathway proteins in 
cancer stromogenesis. 
2. In biopsies, FANCM and Massonʼs trichrome demonstrated a statistically 
significant difference between G1 cancerous stroma and non-cancerous 
areas, but with considerable overlap in staining intensity between the groups. 
Thus, the use of these markers or similar (such as Van Gieson) should be 
avoided in the analysis of stromogenic reaction of PCa despite being re-
commended by some practitioners. 
3. Ki67 gains more and more attention in PCa diagnosis. This study displayed 
grade dependant increase in DAB-positive cells, but adjacent groups are 
indistinguishable; thus, the stain cannot be used in Gleason grading. At the 
same time, Ki67 is one of the most frequently used IHC markers and has 
proved diagnostic value in some neoplasms (as neuroendocrine tumors). 
Precise quantification of Ki67 using microscopes is time-consuming if done 
correctly. Results prove that a reliable analysis can be performed by com-
puter within seconds. The integrated algorithm provided by Histomics has 
flexible settings, thus is universal, and can be used not only for nuclear but 
also for cytoplasmic and membrane stains. 
4. Pathadin software allows experiencing almost all benefits of computer-
assisted analysis of different complexity without any cost: the creation of 
models for any purpose, an independent quantification of stromal and epi-
thelial changes. The concept should give an understanding of what modern 
DP and ML are and how enormous their applicatory function in medicine 
can be. Even a basic multiclass model for prostate segmentation is a time-
saver for pathologists simplifying detection of extraprostatic or perineural 
invasion. 
5. Following provided manuals, a similar model can be created for more 
precise prostate analysis or entirely different tissues.  
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11. FUTURE DIRECTIONS 
Microenvironmental changes in carcinomas are starting to gain more attention 
in many organs, including the prostate. While it was demonstrated that the 
FANCM and MTʼs clinical use is somewhat limited, the difference between 
cancer-free, low, and high-risk carcinomas was seen and is worthy of further 
research. The study also outlined the potential role of homologous recombinant 
pathway proteins in cancer stromogenesis with the necessity of further investi-
gation. 
Pathadin will be further improved and reformated depending on the under-
standing of the current and future trends: the updates constitute the addition of 
new formats, such as DICOM (a possible new standard for digital pathology), 
testing new neural networks, and adding features as stereological analysis. 
When combined with clinical data, the described workflow can be used to 
reliably test new histological markers and evaluate possibilities for application 
in daily practice. 
Currently, coexisting, at some point, digital pathology will inevitably replace 
the microscope. Both the College of American Pathologists and the Royal 
College of Pathologists already provide the guidelines for the implementation of 
digital pathology. The fast spread is synergic with the constantly evolving 
machine learning algorithms. At the same time, the quality of histological slides 
is continuously improved and standardized, meaning that some machine 
learning-related issues described in the manuscript will soon become archaic. 
Today any histologist with access to a scanning device can collaborate with 
a data scientist and train a model without significant expenses. It will lead to a 
point where experts will create models equal to or outperforming the average 
pathologist. It can be imagined how the trained algorithms will also be provided 
and used by the validated labs along with the classical diagnostic manuals. 
Estonia has a perfect potential to become the first fully digital country: high 
quality of histological samples, advance in IT, a small population, and lack of 
pathologists. In this paradigm, the national digital archive covering all country 
hospitals seems reasonable: easy access to morphology in combination with 
clinical data will improve both clinical and scientific routine for pathologists, 
oncologists, and genetics, resulting in benefits for the patient. 
The manuscriptʼs author will continue spreading the ideas of computer-
assisted diagnostics by reviewing the latest solutions and consulting anyone 
willing to start with such an approach. 
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12. SUMMARY IN ESTONIAN 
Adenokartsinoomi mikrokeskkonna muutuste 
kvantifitseerimine ja diagnostilise tähenduse hindamine 
eesnäärmes, rakendades uuemaid digipatoloogilisi 
programmiarendusi 
Sissejuhatus 
Maailmas on eesnäärme adenokartsinoom sageduselt teine pahaloomuline kas-
vaja meestel. 2018. aastal diagnoositi 1 276 106 uut eesnäärme adenokartsinoo-
mi juhtu moodustades 3.8% meeste vähisurmade põhjustest. Eestis moodustas 
2017. aastal eesnäärmekartsinoom 25.2% kõigist vähijuhtudest meestel. Ees-
näärmevähi diagnostika standardiks enne raviotsust on histoloogiline uuring 
nõelbiopsiatest. Histoloogilise diagnoosi lahknevusi biopsiate ja radikaalse 
prostatektoomia (RP) vahel esineb kirjanduse andmetel 23–43% juhtudest.  
Eesnäärmevähi biokeemilise retsidiivi riski alusel, mis on ravivaliku aluseks 
jaotab Uroloogilise Patoloogia Ühing, eesnäärmevähi kolme astmesse G1, G2 ja 
≥G3. Kuna mõned ravivõimalused on rakendatavad vaid madala riskiga haige-
tel, siis on ülimalt oluline viia miinimumini diagnooside lahknevused biopsias 
ja RP-s, eriti G1 astmesse kuuluva vähi korral.  
Üheks võimaluseks vähendada diagnooside lahknevusi pakub Ameerika 
Patoloogide Kolleegium välja strooma hindamist näärmeliste vähikollete vahel 
biopsiates. Vähi mikrokeskkonna muutused on kliiniliste uuringute andmetel 
olulise prognostilise tähtsusega rinna, jämesoole ja teiste organite kartsinoomi-
des. Eesnäärmevähil korreleerub strooma rakulise koostise fenotüübiline muu-
tus kasvaja Gleasoni astmega.  
Strooma muutuste hindamiseks on vajalik eristada selle rakutüüpe: normaal-
sed silelihasrakud, vähi fibroblastid ja müofibroblastid. Selles töös kasutati 
Massonʼi trikroom (MT) värvingut ja immunohistokeemilist (IHK) uuringut 
Fanconi aneemia komplementaarse rühma M (FANCM) antikehaga. FANCM 
osaleb DNA homoloogilise rekombinatsiooni (HR) protsessis ja selle avaldu-
mist normaalses eesnäärme stroomas on varem täheldatud, kuid antud uuring oli 
selle esimeseks süstemaatiliseks hindamiseks eesnäärmevähis. 
Senini strooma hindamiseks kasutatud kvalitatiivsed meetodid on ebapiisava 
täpsusega tuginedes uurija subjektiivsele hinnangule valgusmikroskoobi piira-
tud vaateväljades. Digipatoloogia (DP) võimaldab alusklaasil olevaid histoloo-
gilisi preparaate skaneerides saada digipreparaadid, mida on võimalik täies ula-
tuses automaatselt arvuti-assisteeritult analüüsida ja isegi diagnoosida. Selleks 
on viimastel aastatel arendamisel masinõppe algoritmid (ML). Lõplikku diag-
nostikat ML praegu veel päriselt ei asenda, kuid neil on potentsiaali igapäevases 
rakendustes, näiteks erinevate koeliikide eristamiseks või vähikahtlaste kollete 
automaatseks avastamiseks. ML võimaldab täpselt eristada strooma komponenti 
näärmetest ja analüüsida kumbagi eraldi olenevalt kasutatud värvimismetoodi-
kast. 
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Ehkki viimasel ajal lisandub uusi DP lahendusi, ka vabavarana, pidevalt 
juurde, siis ei olnud väitekirja alustades saada programme, mis võimaldaksid 
ML lihtsal teel rakendada alates esimestest etappidest nagu digipreparaadi anno-




Töö eesmärgiks on kvantifitseerida ja hinnata kartsinoomiga seotud mikrokesk-
konnamuutuste diagnostilist olulisust erinevate Gleasonʼi astmete ümber ning 
nende praktilist kasutusvõimalust biopsiate puhul.  
Ülesanne nõuab esmalt üldisema metodoloogilise probleemi lahendamist 
lihtsalt kasutatava, täpse DP-lahenduse väljatöötamisel, mille tööpõhimõte jäl-
jendaks valgusmikroskobiga töötava patoloogi rutiinset diagnostilist protsessi. 
Loogilises kronoloogilises järjekorras reastatuna on konkreetsed ülesanded 
objektiivse biopsiaanalüüsi tegemiseks järgnevad: 
1. Luua WSI-orienteeritud avatud lähtekoodiga tööriistakomplekt, mis võimal-
dab teha järgmist: 
1.1. Põhivärvianalüüs (K-keskmised, värvikünnised) huvipakkuvas regioo-
nis (region of interest, ROI). 
1.2. Diaminobensidiini (DAB) positiivsete ja negatiivsete rakkuda kvantifit-
seerimist huvipakkuvas regioonis. 
1.2.1. Pakutavate tööriistade abil hinnata DAB-positiivsete rakkude 
loendamise täpsust, kvantifitseerides Ki67 (üks populaarsemaid 
immunohistokeemilisi markereid) erinevate ISUP-klasside PCa-
des. 
1.3. Pildiandmestu komplekteerimist ML-i jaoks digitaliseeritud preparaadi-
klaasidelt. 
1.4.  Treenitud mudeli visualiseerimist ja valideerimist. 
2. Luua ja kinnitada mitmeklassiline mudel, segmenteerides eesnäärme viieks 
komponendiks – näärmed, strooma, närvid, rasv, tühimikud edasiseks sõltu-
matuks analüüsiks. 
3. Kvantifitseerida stromaalsete muutuste korrelatsioon ISUP-klassidega MT ja 
FANCM värvitud proovides, kasutades kaasasolevaid tarkvaratööriistu: 
3.1. Süstemaatiliselt hinnata FANCM värvingut eesnäärmes. 
3.2. Objektiivselt hinnata RP-proovides PCa-ga seotud mikrokeskkonna-
muutuste olulisust ja selgitada edasiste uuringute teostamise ratsionaal-
sus piiratud biopsiate mahul. 
3.3. Hinnata biopsiates PCa-ga seotud mikrokeskkonnamuutuste praktilise 
diagnostika rakendamise võimalusi. 
Metodoloogiat peetakse mõnevõrra universaalseks ning sobivaks kasutamiseks 





Materjalid ja metoodika 
Uuringus kasutati histoloogilisi koematerjale 385 patsiendilt, kellele ajavahe-
mikus 2007–2010 teostati Ida-Tallinna keskhaiglas nii eesnäärme biopsiad kui 
radikaalne prostatektoomia (RP). Uuritavatest 232 juhul (60%) olid biopsia ja 
RP G astmed samad, biopsiates diagnoositud G astme hilisem suurendamine RP 
alusel esines 128 (34%) ja vähendamine 25 (6%) korral. Biopsiad, mille 
diferentseerumise aste RP uuringul suurenes, olid kõige sagedamini G1 kokku 
82 juhul. Negatiivse kontrollina on kasutati 11 lahangu materjali, mille puhul ei 
esinenud eesnäärmehaigusi ega muid pahaloomulisi kasvajaid. 
Histoloogiliste preparaatide värvimismeetoditest kasutati G astme hindami-
sel, selekteerimisel ja MA tarvis koetüüpide märgistamisel rutiinset hematoksü-
liin-eosiin värvingut (H&E), strooma koostise hindamiseks histokeemilist MT 
meetodit ja IHK värvingut inimese FANCM-vastase primaarse antikehaga. 
Mitootilist aktiivsust hinnati IHK värvingu alusel Ki67 monoklonaalse anti-
kehaga. Mikropreparaadid digitaliseeriti kasutades 3DHistech Pannoramic Flash 
III 250 skannerit 20x suurendusega (eraldusvõime 0,24 μm/pikselit).  
Digianalüüsiks loodi ja valideeriti tarkvara Pathadin (Pathology + Paladin), 
mille lähtekood, kasutatud andmekogud ja mudelid on esitatud repositooriumis: 
https://gitlab.com/Digipathology/Pathadin (https://github.com/geodza/Pathadin) 
Rakendades Pathadin valideeritud ML mudelit, sai eesnäärme preparaatides 
automaatselt eristada strooma komponente näärmetest paralleelselt kõigis 
kasutatud värvingutega preparaatides ja kvantifitseerida nende koostist algul RP 
ja seejärel biopsiates. FANCM ja MT hindamisel kasutati strooma värvumis-
indeksit (SSI, stromal staining index), positiivselt värvunud strooma osakaalu 
(%) kogu strooma pindalast. Kollageeni osakaalu hinnati MT värvingul seadis-
tatud HSV (hue, saturation, value) värvilävendi alusel. Ki67 avaldumist määrat-
leti positiivselt värvunud näärmeliste rakutuumade suhtega kõigi epiteelsete 
rakutuumade arvu 1 mm2 (%) kohta.  
 
 
Tulemused ja arutelu 
MT värving RP preparaatides näitas ilmekalt astmelist kollageeni hulga suure-
nemist eesnäärmevähi ümbruse stroomas, mille suhteline hulk hinnatuna SSI 
alusel kasvas sõltuvalt vähi G astmest. Keskmine SSI oli statistiliselt kõrgem 
juba G1 astme vähis (40.5 %) võrreldes kontrolliga (28%; p< 0.001). Statistili-
selt oluline kollageeni hulga suurenemine ilmnes kui võrreldi keskmisi SSI 
väärtusi kasvajavabas koes samast prostatast (26.9 %) pärineva vähi stroomaga: 
G1 (40.5 %), G3 (50.3%) või G4 (83%; kõigil p< 0.001). 
FANCM immuunohiostokeemiline värving RP normaalsetes eesnäärme 
stroomarakkudes on tugev ja difuusne, olles seega nende spetsiifiline marker. 
FANCM avaldumine väheneb proportsionaalselt eesnäärmevähi G astme suure-
nemisega. Keskmine SSI vähenes statistiliselt oluliselt juba G1 vähis (28%) 
võrreldes kasvajavaba kontrolliga (39%) ja koega sama kasvaja kõrvalt (41%), 
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p <0,001 mõlemal. FANCM avaldumistaseme statistiliselt oluline langus tuvas-
tati ka G2 (25%) võrreldes G3 vähiga (18%), p = 0,005. Spearmanʼi korrelat-
sioonikordaja SSI ja G astmegruppide vahel oli −0,9 (p <0,001). FANCM SSI 
muutused stroomas erinevates vähi G astmegruppides olid vastupidised MT SSI 
muutustele, seega on mõlemad markerid strooma rakulise koostise näitajad. 
FANCM avaldumistase vähi naabruses olevas normaalses stroomas ei erine-
nud tasemest vähivabas kontrollis, mis viitab, et puudub potentsiaalselt ees-
näärmevähi riski suurendav FANCM baasavaldumise muutus uuritavas valimis. 
FANCM tulemused osundavad DNA HR, mille tähtsus on varasemast teada 
näärmetes, võib omada tähendust ka vähi stroomas.   
MA programm suutis tõhusalt eristada ja arvutada strooma markerite MT ja 
FANCM SSI kui ka Ki67 avaldumisprotsenti vähikoes. Pärast RP analüüsi 
rakendati MT ja FACNM värvingut koos valideeritud DP algoritmiga biopsiate 
analüüsil, mille koemaht on RP-ga võrreldes piiratud. Kuna praktilises kliini-
lises olukorras tuli G1 vähiga biopsiates kõige sagedamini ette diagnoosi muut-
mist RP alusel (82 korral), siis kujunes tööhüpoteesiks, kas strooma muutuste 
alusel oleks võimalik ennustada biopsias G1 vähi naabruses kõrgema G astmega 
vähi esinemist või vähivabas biopsias mistahes astmega vähi esinemist. Arves-
tades, et eesnäärme strooma histoloogiline ehitus sõltub anatoomilisest tsoonist, 
kaasati analüüsi ainult perifeerse tsooni biopsiad, mis moodustasid valimist 
enamuse.  
Kontrollgrupi (CG) moodustasid G1 vähiga biopsiad, mille diagnoos RP alu-
sel ei muutunud. Testgruppi (TG) kuulusid kõik üles gradeeritud G1 biopsiad, 
hõlmates nii vähiga (TGC) kui vähivabasid bioptaate (TGW) samalt patsiendilt. 
Gruppide kollageeni hulga võrdlus MT värvingu alusel näitas, et keskmine 
SSI kontrollgrupi (CG) biopsiates oli 41% (20- 78%, SD= 11)) üles gradeeritud 
vähiga grupis (TGC) 44% (23–89%, SD= 15) ja vähivabades bioptaatides37 % 
(15–57%, SD= 9). Kontroll-testgruppide vahel esines osalist kattuvust ja seega 
puudus statistiline erinevus (p=0.84). Erinevus TGC ja TGW rühmade vahel oli 
statistiliselt erinev (p=0.012).  
FANCM värvingu alusel positiivsete strooma elementide võrdlus gruppides 
näitas, et keskmine SSI CG grupis oli 36% (13- 59%, SD= 11); 34% (9–58%, 
SD= 13) TGC grupis ja 44 % (22–69%, SD= 11) TGW grupis. CG ja TG grup-
pide vahel esines osaline kattuvus ja seega puudus statistiline erinevus (p=0.5). 
Erinevus TGC ja TGW rühmade vahel oli statistiliselt erinev (p<0.001). 
Tulemused näitavad, et MT ja FANCM värvingud võimaldavad mõlemad 
eristada olulisi strooma koostise erinevusi vähi ümbruses võrreldes samast ana-
toomilisest piirkonnast pärineva vähivaba koega. G1 vähk gradeeriti RP-s kõige 
sagedamini G2 astmeks, mis võib olla põhjuseks, et üles gradeeritud grupis 
esinevad muutused võrreldes G1 grupiga olid liiga vähesed, et oleksid kummagi 
värvinguga usaldusväärselt ennustatavad, et neid võiks soovitada rutiinses 
diagnostikas. Siiski, kuna TG grupis esines ka kõrgema G astme vähki ja üle 
95% intervalli SSI väärtusi, oleks mõeldav leida G1 vähis SSI lävend, mis 
ennustaks kõrgema astme vähi võimalikku esinemist bioptaadi naabruses.  
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Kuigi MT ja FANCM värvingu tulemused olid sarnased, oli FANCM värvin-




Töö põhieesmärgiks oli objektiivselt analüüsida kartsinoomiga seotud mikro-
keskkonnamuutuste hulka ja diagnostilist olulisust erinevate Gleasonʼi astmete 
ümber ning selliste muutuste praktilist kasutusvõimalust, eelkõige biopsiate 
puhul. 
Võttes arvesse mikroskoobil olevaid piiranguid histoloogiliste muutuste täp-
seks hindamiseks, töötati välja ja katsetati kaasaegsetel digitaalsetel patoloogia-
lahendustel põhinevat tööriista. 
Loogilises kronoloogilises järjekorras on järeldused järgnevad: 
1. Avatud lähtekoodi baasil loodud tööriist WSI-orienteeritud analüüsiks, Pat-
hadin, toimis edukalt järgmistes valdkondades: 
1.1. Kiire, objektiivne ja korratav histoloogiliste proovide värvingute uuri-
mine, kasutades värvianalüüsi algoritme (HSV lävend). 
1.2. DAB-positiivsete tuumade kvantifitseerimine Ki67-ga värvitud proo-
vides. Analüüs näitas, et vaatamata Gleasonʼi astmetest sõltuvatele eri-
nevustele piirab külgnevate klassigruppide kattumine kliinilist raken-
dust. 
1.3. Pildiandmestu ettevalmistamine masinõppe algoritmide treenimiseks. 
1.4. Treenitud masinõppemudeli testimine, visualiseerimine ja valideeri-
mine. 
2. Katsematerjali edasiseks sõltumatuks analüüsiks loodi ja valideeriti U-Net 
mudel, mis suudab eristada näärmeid, stroomat, närve, rasva ja tühimikke. 
3. Pathadinʼi keskkonnas kasutatud treenitud mudeli ja värvianalüüsi algo-
ritmide kombinatsiooni kasutati mikrokeskkonna muutuste hindamiseks eri-
nevate vähkkasvajate klassifitseerimise rühmade ümber: esiteks radikaalse 
prostatektoomia proovides ning seejärel biopsiates, et mõista praktilist väär-
tust diagnostikale. 
3.1. Radikaalse prostatektoomia proovides: 
3.1.1. Uudne marker FANCM, mida süstemaatiliselt kirjeldati esma-
kordselt eesnäärme adenokartsinoomi korral. See näitas strooma-
spetsiifilisust ja kartsinoomi klassist sõltuvat langust kartsinoomi 
mikrokeskkonnas ning viitas homoloogse rekombinantse raja 
võimalikku mõju vähi stroomas. FANCM valgu algtaseme eks-
pressioon normaalses eesnäärme stroomas ei mõjutanud tundlik-
kust adenokartsinoomi suhtes. 
3.1.2. Massoni trikroom (kollageeni analüüsitud värvimine) näitas sa-
muti kartsinoomi klassist sõltuvat muutust ekspressioonis ning 
erinevust vähkkasvajast mõjutatud ja normaalsete piirkondade 
vahel. 
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3.1.3. Mõlemal markeril esines märkimisväärne kattumine ekspressioo-
nis külgnevate klassigruppide vahel. Kattuvus oli minimaalne 
madalate (G1) ja kõrge astmega (G4 ja G5) kartsinoomide ning 
vähkkasvajast mõjutatud ja normaalsete piirkondade vahel. 
3.2. Biopsiates: 
3.2.1. Leidis kinnitust, et G1 eesnäärme kartsinoomi diagnoositakse ja 
hinnatakse kõrgemale astmele kõige sagedamini. 
3.2.2. Strooma koostise kvantifitseerimine FANCM-i ja Massoni tri-
kroomvärvingu põhjal näitas statistiliselt olulist erinevust G1 
diferentseerumisega vähkkasvajast mõjutatud ja normaalsete 
piirkondade vahel. 
3.2.3. Vaatamata kinnitatud statistilisele olulisusele, on G1 ja normaal-
sete piirkondade ekspressiooni märkimisväärne kattumine piiran-
guks FANCM-i ja Massoni trikroomvärvingu diferentsiaaldiag-
nostika kasutamisel biopsiates ja seeläbi ka kliinilises praktikas. 
 
Loodud metodoloogia on universaalne. Andmehoidlas (https://gitlab.com/ 
Digipathology/Pathadin või https://github.com/geodza/Pathadin) olevate juhiste 
ja näidiste kasutamine võib toimida juhendina kõigile, kes soovivad mõista 
arvutipõhise patohistoloogilise diagnostika põhitõdesid. Samuti võib see aidata 
kaasa uute mudelite loomisele või mikrokeskkonnamuutuste kvantifitseerimi-
sele erinevates kudedes. 
 
Praktilised soovitused 
1. FANCM, homoloogse rekombinantse raja valk, paistab olevat uudne, kõrgelt 
strooma-spetsiifiline immunohistokeemiline marker eesnäärmes, mis näitab 
astmest sõltuvat langust kartsinoomi mikrokeskkonnas. See annab ülevaate 
homoloogse rekombinantse raja valkude potentsiaalsest rollist kartsinoomi 
stromogeneesis. 
2. Biopsiates demonstreerisid FANCM ja Massoni trikroomvärving statistiliselt 
olulist erinevust G1 astme kartsinoomist mõjutatud strooma ja normaalsete 
regioonide vahel, kuid värvingu intensiivsuses esines gruppide vahel mär-
kimisväärne kattumine. Seetõttu tuleks nende või sarnaste markerite (nt. Van 
Gieson) kasutamist vältida PCa stromogeensete reaktsioonide analüüsil, 
kuigi nende kasutamine on mõndade praktikute poolt soovitatud. 
3. Ki67 püüab PCa diagnostikas järjest enam tähelepanu. Käesolevas uuringus 
leiti astmest sõltuv tõus DAB-positiivsete rakkude hulgas, kuid eristatavad ei 
ole lähedalpaiknevad grupid, seetõttu ei saa värvingut kasutada Gleasoni ast-
mete määramisel. Samaaegselt on Ki67 üks enimkasutatavaid immunohisto-
keemilisi markereid, millel on tõestatud diagnostiline väärtus mõndade neo-
plaasiate puhul (nt. neuroendokiinsed kasvajad). Korrektselt teostatud Ki67 
kvantifitseerimine valgusmikroskoopi kasutades on aga aeganõudev. Tule-
mused tõestavad, et arvutit kasutades on võimalik usaldusväärne analüüs 
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teostada sekundite jooksul. Näiteks vabavarana saadaval Histomicsʼi poolt 
pakutud integreeritud algoritmil on paindlikud sätted ning on seega univer-
saalne, võimaldades kasutust mitte ainult rakutuuma värvingutel, vaid ka 
tsütoplasmaatiliste ja membraanivärvingute puhul. 
4. Pathadin tarkvara võimaldab kogeda pea kõiki komplekse eritasemelise 
arvutipõhise analüüsi hüvesid ilma kahjudeta: mudeleid on võimalik luua 
igal eesmärgil, eelkõige strooma ja epiteliaalsete muutuste iseseisvaks kvan-
tifitseerimiseks. Kontsept peaks andma ülevaate kaasaegsest DP-st ja ML-ist 
ning kui suurejoonelised võivad olla nende kasutusvõimalused meditsiinis. 
Patoloogide jaoks vähendab ajakulu ka lihtne mitmeklassiline mudel ees-
näärme segmenteerimisest, lihtsustades ekstraprostaatiliste või perineuraal-
sete invasioonide detekteerimist. 
5. Pakutud juhendeid järgides on võimalik luua sarnane mudel spetsiifilisemaks 
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